RETRACTABLE TECHNOLOGIES INC_December 31, 2024

 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

 FORM 10-K
 (Mark One)
 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2024

 or

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from to

 Commission file number 001-16465

 Retractable Technologies, Inc.
 (Exact name of registrant as specified in its charter)

 Texas

 75-2599762

 (State or other jurisdiction of
incorporation or organization)

 (I.R.S. Employer
Identification No.)

 511 Lobo Lane

 Little Elm, Texas

 75068-5295

 (Address of principal executive offices)

 (Zip Code)

 972 - 294-1010
 Registrant's telephone number, including area code
 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class

 Trading Symbol

 Name of each exchange on which registered

 Common Stock

 RVP

 NYSE American LLC

 Securities registered pursuant to Section 12(g) of the Act:
 Preferred Stock
 (Title of class)

 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

 The aggregate market value of the common equity held by non-affiliates as of June 30, 2024, was $ 14.6 million, assuming a closing price of $1.08 and outstanding shares held by non-affiliates of 13,487,595.

 APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY
 PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes No

 (APPLICABLE ONLY TO CORPORATE REGISTRANTS)

 Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date. As of March 10, 2025, there were 29,937,159 shares of our Common Stock outstanding, excluding treasury shares.

 DOCUMENTS INCORPORATED BY REFERENCE

 Portions of the registrant's Proxy Statement filed on March 28, 2025 for the Annual Meeting of Shareholders to be held May 9, 2025 are incorporated by reference into Part III hereof.

 FORM 10-K
 For the Fiscal Year Ended December 31, 2024

 Item 1. Business

 Item 1A. Risk Factors

 Item 1B. Unresolved Staff Comments

 Item 1C. Cybersecurity

 Item 2. Properties

 Item 3. Legal Proceedings

 Item 4. Mine Safety Disclosures

 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

 Item 6. [Reserved]

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation

 Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 Item 8. Financial Statements and Supplementary Data

 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item 9A. Controls and Procedures

 Item 9B. Other Information

 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 Item 10. Directors, Executive Officers and Corporate Governance

 Item 11. Executive Compensation

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13. Certain Relationships and Related Transactions, and Director Independence

 Item 14. Principal Accounting Fees and Services

 Item 15. Exhibits, Financial Statement Schedules

 Item 16. Form 10-K Summary

 SIGNATURES

 i

 FORWARD-LOOKING STATEMENT WARNING
 Certain statements included by reference in this filing containing the words "could," "may," "believes," "anticipates," "intends," "expects," and similar such words constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Any forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, material changes in demand, tariffs, our ability to maintain liquidity, our maintenance of patent protection, our ability to maintain favorable third party manufacturing and supplier arrangements and relationships, foreign trade risk, our ability to access the market, production costs, the impact of larger market players in providing devices to the safety market, and other factors referenced in Item 1A. Risk Factors. Given these uncertainties, undue reliance should not be placed on forward-looking statements.
 Item 1. Business.
 DESCRIPTION OF BUSINESS
 General Development of Business
 Retractable Technologies, Inc. was incorporated in Texas in 1994. Our business is the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. We have manufacturing facilities in Little Elm, Texas and use manufacturers in China as well. Our syringes are well-suited for administering vaccinations and our revenues materially increased in 2020-2021 due to COVID-19 vaccination demand. Our revenues decreased as sales to the U.S. government for vaccinations wound down in the first quarter of 2022, although international vaccination demand positively and materially impacted sales throughout 2022 and the first quarter of 2023.
 In September 2024, a new 100% tariff on syringes and needles imported from China became effective. Additionally, effective February 4th and March 4th of 2025, tariffs on Chinese imports were increased by an aggregate total of 20%. The increase of 20% applied not only to syringes and needles, but to other products we import from China. While we have manufacturing capabilities to manufacture most of the products we currently sell domestically, some of our products are sourced exclusively from China. Approximately $1.6 million was spent on tariff expenses from September - December 2024 when the tariff rate was 100% on syringes and needles imported from China. From January 1 to March 21, 2025 under a system of increasing tariffs, we have paid a total of approximately $951,000 on tariff expenses. We are currently working to lessen the financial impact of the tariffs, including shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint needles to our domestic manufacturing facility. Additionally, we have recently adapted some equipment to increase our domestic manufacturing capabilities. These adaptations will allow us to manufacture 0.5 mL syringes domestically, reducing our reliance on imports for those products. We expect that commercial quantities will be available for sale in the second half of 2025.
 Additionally, in recent past years, we increased our domestic manufacturing capacity for product lines typically used in the administration of vaccines, funded in part by the Technology Investment Agreement, as amended ("TIA") with the United States Government Department of Defense, U.S. Army Contracting Command-Aberdeen Proving Ground, Natick Contracting Division & Edgewood Contracting Division (ACC-APG, NCD & ECD) on behalf of the Biomedical Advanced Research and Development Authority (BARDA). The TIA funded the $81.0 million facilities expansion and purchase of new manufacturing equipment and related ancillary equipment. At our own expense, we constructed a new warehouse onsite for housing finished goods and raw materials to be used in the manufacturing process as well as an expansion to our administrative offices. The TIA (under its April 2023 successor agreement, Other Transaction Agreement) governs ongoing terms until June 30, 2030 which include maintenance of equipment, availability of capacity, and U.S. government preference in the event of a public health emergency.

 Description of Business
 Our goal is to become a leading provider of safety medical products. Our principal products were designed to protect healthcare workers, patients, and others from needlestick injuries, cross-contamination through reuse, and reduce disposal costs.
 Our dominant revenue-generating products are our injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. Most of our products incorporate a feature whereby our needles retract which is a safety feature designed to protect healthcare workers from needlestick injuries. Our VanishPoint 1mL syringes meet the criteria set by pharmaceutical manufacturers for low dead space, which results in a reduction of wasted medication caused by residual medication remaining in the syringe after a dose has been administered. In some instances, the low dead space allows for additional doses to be obtained from a medication vial.
 VanishPoint syringe sales have historically comprised most of our sales. Syringe sales were 68.5%; 78.3%; and 91.5% of our revenues in 2024, 2023, and 2022. EasyPoint products accounted for 27.1%; 16.6%; and 5.0% of sales in 2024, 2023, and 2022.
 From 2020 through the first quarter of 2022, the U.S. government was a significant customer due to efforts to vaccinate the U.S. population against COVID-19. Sales to the Department of Health and Human Services for safety syringes totaled $15.7 million in 2022 (concentrated in the first quarter), $113.7 million in 2021, and $31.6 million in 2020. The orders from the Department of Health and Human Services included reimbursement of freight costs. As such, comparability of 2024 revenue and expenses to revenues and expenses in recent years may be challenging. Moreover, we believe domestic customers may have retained product provided for vaccination purposes in inventory, leading to a decrease in overall demand. The extent to which these supplies still exist and the effect it has on future ordering patterns is difficult to estimate.
 We currently have under development additional safety products that add to or build upon our current product line offering. Such products are not expected to be commercially available in 2025.
 Our products are sold to and used by healthcare providers. Historically, an overwhelming majority of our products have been sold domestically. However, in 2022, 44.9% of our sales were international sales and in the first quarter of 2023, 50.7% of our sales were international. For the remainder of 2023 and for 2024, international sales were closer to 10% of total sales. The increase in 2022 and the first quarter of 2023 is attributable to higher international revenues from vaccination efforts which lagged domestic vaccination sales by a year or more.
 In years not dominated by direct sales to the U.S. government, representatives of group purchasing organizations ("GPOs") and purchasing representatives (rather than the end-users of the product) make the vast majority of decisions relating to the purchase of medical supplies. The GPOs and larger manufacturers often enter into contracts which can prohibit or limit entry in the marketplace by competitors.
 We distribute our products throughout the U.S. through general line and specialty distributors. We also use international distributors. We have developed a national direct marketing network in order to market our products to health care customers and their purchaser representatives.
 Sources and Availability of Raw Materials
 Our product components, including needle adhesives and packaging materials, are purchased from various suppliers. There is no current scarcity of such materials or such suppliers.
 Intellectual Property
 Intellectual property rights, particularly patent rights, are material to our business. The patent rights are jointly owned by the Company and Thomas J. Shaw, our founder and CEO, and have varying expiration dates. Under the terms of an exclusive license agreement that has been in effect since 1995, the Company is exclusively licensed to use the patent

 rights held by Mr. Shaw, and Mr. Shaw generally receives a 5% royalty on gross sales of products subject to the license and he receives 50% of the royalties paid to the Company by certain sublicensees of the technology subject to the license.
 Recent and expected modifications to our VanishPoint products will effectively cause the modified VanishPoint products to have extended patent expiration dates. Following the expiration of patents related to the old design, competitors may attempt to copy aspects of such prior design, but not the current design.
 Patents related to recent modifications to the VanishPoint syringes and core technology of the VanishPoint syringes will expire during the years 2028 through 2032. Other patent applications covering inventions applicable to the VanishPoint syringes are pending.
 The Company has unexpired patents which relate to the EasyPoint technology and other products as well.
 The Company has registered the following trade names and trademarks for our products: VanishPoint, EasyPoint, Patient Safe, VanishPoint logos, RT and design, the VanishPoint and design, the spot design and the Company slogans "The New Standard for Safety" and "We Make Safety Safe".
 Seasonality
 Historically, unit sales have increased during the flu season.
 Government Approval and Government Regulations
 Compliance with government regulations represents an important part of our business. As a manufacturer of medical devices and operating under the TIA, we are subject to stringent regulatory requirements. In addition, we are also subject to maintain systems to monitor and report our findings to various regulatory bodies. We are also subject to audit by those bodies and/or third parties acting as proxies to verify our compliance with such regulations. The cost of compliance can be significant in terms of financial and human resource commitments. These costs are ongoing and may become more significant if the regulatory landscape changes.

 The development, manufacture, marketing, sale, promotion, and distribution of our products are subject to government regulation by the U.S. Food and Drug Administration (FDA) and similar international regulatory agencies. Regulation by various international, federal and state agencies address the development and approval to market medical products, as well as approval and supervision of manufacturing, labeling, packaging, supply chains, distribution and record-keeping.
 For all products manufactured for sale in the domestic market, we have given notice of intent to market to the FDA, and the devices were shown to be substantially equivalent to the predicate devices for the stated intended use. For all products manufactured for sale in the domestic market and foreign market, we hold a Quality Management System certification to ISO 13485:2016. Additionally, for all products manufactured for sale into the applicable countries, we hold a Quality Management System certification in compliance with the Medical Device Single Audit Program (MDSAP). We do not currently hold a CE mark but are pursuing certification under EU MDR 2017/745.
 Compliance with domestic and international laws and regulations may affect our business. Among other effects, health care regulations and significant changes thereto may substantially increase the time, difficulty, and costs incurred in developing, obtaining, and maintaining approval to market, and marketing newly developed and existing products. We expect this regulatory environment will continue to require effort and investment to ensure compliance. Failure to comply could delay the release of a new product or result in regulatory and enforcement actions, the seizure or recall of a product, the suspension or revocation of the authority necessary for a product's production and sale, and other civil or criminal sanctions including fines and penalties.
 The regulation of data privacy and security, and the protection of the confidentiality of certain personal information (including patient health information, financial information, and other sensitive personal information), is increasing. For example, the European Union, various other countries, and various U.S. states (e.g., California) have

 enacted stricter data protection laws that contain enhanced financial penalties for noncompliance. Similarly, the U.S. Department of Health and Human Services has issued rules governing the use, disclosure, and security of protected health information, and the FDA has issued further guidance concerning cybersecurity for medical devices. In addition, certain countries have issued or are considering "data localization" laws, which limit companies' ability to transfer protected data across country borders. Failure to comply with data privacy and security laws and regulations can result in business disruption and enforcement actions, which could include civil or criminal penalties.
 The sale of medical products is subject to laws and regulations pertaining to health care fraud and abuse, including state and federal anti-kickback, anti-self-referral, and false claims laws in the United States.
 We will continue to comply with applicable regulations of all countries in which our products are registered for sale.
 We believe that we do not incur material costs in connection with compliance with environmental laws.
 Competitive Conditions
 Our competitive position with respect to product acceptance and market share remains much the same as before the COVID-19 pandemic. From a business perspective, our competitive position has been made more difficult with the implementation of tariffs on products we import from China. In September of 2024, a 100% tariff was placed on syringes and needles, and in 2025 an additional 20% tariff was placed on other products we import which had not previously been covered under the 2024 tariffs. We continue to face fierce competition from much larger and more established companies across the U.S. healthcare market. While our products were widely used in the mass vaccination efforts during the COVID-19 pandemic, there is no assurance that we will be able to gain market share due to our relative size and presence in the overall U.S. healthcare market.
 Becton, Dickinson and Company ("BD"), a global company which we had previously considered our primary competitor, spun off a portion of its syringe, needle, and injection product division as Embecta Corp. ("Embecta") in April 2022. Embecta, which specializes in diabetes management, along with BD itself, are formidable competitors with greater market share and greater resources than us.
 We compete primarily on the basis of healthcare worker and patient safety, product performance, and quality. We believe our competitive advantages include, but are not limited to, our leadership in quality and innovation. We believe our products continue to be the most effective safety devices in today's market. Our VanishPoint 1mL syringes meet the criteria set by pharmaceutical manufacturers for low dead space, which results in a reduction of wasted medication caused by residual medication remaining in the syringe after a dose has been administered. In some instances, the low dead space allows for additional doses to be obtained from a medication vial. Our syringe products include passive safety activation, require less disposal space, and are activated while in the patient, reducing exposure to the contaminated needle. Our price per unit is competitive or even lower than the competition once all the costs incurred during the life cycle of a syringe are considered. Such life cycle costs include disposal costs, testing and treatment costs for needlestick injuries, and treatment for contracted illnesses resulting from needlestick injuries.
 EasyPoint retractable needles offer unique safety benefits not found in other commercially available safety needles. Manually activated safety needles that compete with EasyPoint must be removed from the patient, exposing the contaminated needle prior to activation of the manual safety mechanism. EasyPoint needles allow for activation of the automated retraction mechanism while the needle is still in the patient, reducing exposure to the contaminated needle and effectively reducing the risk of needlestick injuries. EasyPoint retractable needles are compatible with Luer-fitting syringes, including pre-filled syringes. In addition, EasyPoint retractable needles may be activated with fluid in the syringe, making it applicable for aspiration procedures such as blood collection.
 Employees
 As of March 10, 2025, we had 227 employees. 221 of such employees were full time employees. We provide equal employment opportunities to all employees and applicants for employment without regard to race, color, religion,

 gender, national origin, age, disability, marital status, ancestry, veteran status, workers' compensation status or any other characteristic protected by federal, state, or local law. We have adopted a policy of zero tolerance for any form of unlawful discrimination or retaliation. We continue to evaluate current compensation rates and job descriptions with industry standard salary surveys to maintain competitive wages.

 We recognize that we are now more reliant on our manufacturing workforce than in recent years as a result of tariffs imposed on the import of our products from our overseas manufacturers. As we continue to increase our output of domestically produced products and decrease our overall import mix, a strong and reliable workforce is essential to our success. As such, we are committed to attracting and retaining talent through market-competitive wages and benefits as well as providing a safe and supportive working environment.

 Available Information
 We make available, free of charge on our website (www.retractable.com), our Form 10-K Annual Report and Form 10-Q Quarterly Reports and Current Reports on Form 8-K (and any amendments to such reports) as soon as reasonably practical after such reports are filed.

 Item 1A. Risk Factors.
 You should carefully consider the following material risks facing us. If any of these risks occur, our business, results of operations, or financial condition could be materially affected.
 Recent Tariffs and Other Foreign Trade Policy Risks
 We are subject to risks associated with foreign trade policy. In 2024, we used Chinese manufacturers to produce 83.9% of our products.
 Recently enacted tariffs on our products are expected to have a material negative impact to our results of operations and financial position. We are working to lessen the financial impact of the tariffs, including shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint needles to our domestic manufacturing facility, but these actions are expensive, and the timeline remains uncertain. In addition, the tariffs implemented in 2025 are expanded beyond the original 2024 tariffs placed on syringes and needles. Notwithstanding our efforts to shift the majority of our manufacturing to our domestic facility, we are still reliant on our Chinese manufacturers to provide products we are not able to manufacture. We expect a material increase in the costs of imported goods which is expected to materially impact our operations. However, we have recently adapted some equipment to increase our domestic manufacturing capabilities.

 While we are committed to decreasing our reliance on imported products, and decreasing the negative financial impact such tariffs carry, there is no guarantee that our efforts will be successful. To the extent possible, we are working to increase our domestic production capacity and efficiency to be cost-competitive with our international manufacturers on a pre-tariff basis.

 In the event that we become unable to purchase product from our Chinese manufacturers or produce those products domestically, we may need to find an alternate manufacturer for the blood collection set, IV catheter, Patient Safe syringe, 0.5mL insulin syringe, 0.5mL autodisable syringe, and 2mL, 5mL, and 10mL syringes. Even with increased domestic production, we may not be able to avoid a disruption in supply.
 We derived 11.1% of our revenues in 2024 from international sales. International sales, particularly in emerging market countries, are further subject to a variety of regulatory, economic, and political risks as well. Among the political risk we face with regard to international sales is the risk that our products may be subject to reciprocal tariffs in foreign countries in reaction to recently enacted and threatened tariffs by the U.S. The overall risk to our successful efforts in international markets is unknown and difficult to predict.

 We Are Concerned that Our Stock Price is Not Correlated with Value
 As of December 31, 2024, our market capitalization was $20.7 million (based on a $0.69 per share closing price) and total stockholders' equity was $87.2 million. Our stock price reached a low of $0.57 per share in 2024 despite our strong balance sheet. We are therefore concerned that our stock price is not correlated with our value.

 Our Customers Have Excess Product In Inventory and We Cannot Predict When It Will Be Depleted
 We believe domestic customers have retained Retractable products (as well as competitive products) purchased or provided for vaccination purposes in inventory, leading to a decrease in demand for our products. It is unclear when the excess inventory surplus will clear. Until the inventory is depleted, we expect domestic demand to continue to be depressed. The extent to which surplus product still exists, and the potential impact it may have on future orders, is uncertain.

 We Are Challenged by Uncertainties in Obtaining and Enforcing Intellectual Property Rights
 Our main competitive strength is our technology. We are dependent on patent rights, and if the patent rights are invalidated or circumvented, our business would be adversely affected. Patent protection is considered, in the aggregate, to be of material importance in the design, development, and marketing of our products.
 Syringes comprised 68.5% of sales in 2024. When the patents of the VanishPoint syringes and other products expire, we may experience a significant and rapid loss of sales, and our competitive position in the marketplace may weaken if other competitors use our technology. Such occurrences could have a material adverse effect on profitability.
 We do not maintain patent or trademark protection in all foreign countries, but, where possible, have taken steps to protect our patents and trademarks in those countries where we market our products or where we believe other manufacturers are most likely to attempt to replicate our technology. Our lack of patent and trademark protection in certain foreign countries heightens the risk that our designs may be copied by a competitor in those countries.
 We Are Vulnerable to New Technologies
 Because we have a narrow focus on particular product lines and technology (currently, predominantly retractable needle products), we are vulnerable to the development of superior competing products and to changes in technology which could eliminate or reduce the need for our products. If a superior technology is created, the demand for our products could greatly diminish.
 Our Competitors Have Greater Resources
 Our competitors have greater financial resources, larger and more established sales and marketing and distribution organizations, and greater market influence, including long-term contracts. These competitors may be able to use these resources to improve their products through research and acquisitions or develop new products which may compete more effectively with our products. If our competitors choose to use their resources to create products superior to ours, we may be unable to sell our products and our ability to continue operations would be weakened.
 For instance, Becton, Dickinson and Company ("BD"), a global company which we had previously considered our primary competitor, spun off a portion of its syringe, needle, and injection product division as Embecta Corp. ("Embecta") in April 2022. Though newly formed, Embecta licenses existing BD intellectual property and has continued to use the BD branding on its products and is provided with certain other services by BD. Embecta's 2024 annual report indicated that the company had 2,100 employees, as compared to our workforce of 227 employees. With resources greatly in excess of our own, we expect Embecta will be a formidable competitor.

 We Are Controlled by One Shareholder
 Thomas J. Shaw, our President and Chief Executive Officer, has investment or voting power over a total of 53.3% of the outstanding Common Stock as of March 10, 2025. Mr. Shaw therefore has the ability to direct our operations and financial affairs and significant influence to elect members of our Board of Directors. His interests may not always coincide with the Company's interests or the interests of other stockholders. This concentration of ownership, for example, may have the effect of delaying, deferring, or preventing a change in control, impeding a merger, consolidation, takeover, or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could materially adversely affect the market price of our Common Stock. The concentration of ownership may likewise influence Mr. Shaw's continued employment and position as President, CEO, and Chairman of the Board. Mr. Shaw's rights under the Technology License Agreement, as the owner of the technology we produce, present similar conflicts of interest.
 Defensive Measures to Deter Hostile Takeovers
 On November 16, 2021, we and Mr. Shaw entered into the Third Amendment to Technology License Agreement (the "Amendment"). The Amendment expands the scope of the Technology License Agreement and provides additional protection to the parties in the event of a Hostile Takeover, as defined by the Amendment. Under the Amendment, under certain conditions, Mr. Shaw is granted the unilateral right to terminate the Technology License Agreement or cancel or convert a license thereunder from exclusive to nonexclusive following a Hostile Takeover.
 Additionally, as a public Texas corporation, we are generally prohibited from entering into a business combination with a person who acquires twenty percent or more of our stock for three years unless either: (1) the combination or acquisition is pre-approved by our Board; or (2) the combination is approved by affirmative vote of the shareholders of at least two-thirds of the outstanding voting shares entitled to vote, excluding the affiliated shareholder. As such, independent of the rights granted to Mr. Shaw under the Amendment, as beneficial owner of 53.3% of our stock and Chairman of the Board, Mr. Shaw has considerable influence on all business combination decisions.
 Supply Chain Disruptions Could Negatively Impact our Profitability

 Our operations have historically been dependent on timely delivery of finished goods from our Chinese manufacturers and timely delivery of sufficient quantities of components and raw materials for domestic manufacturing. As mentioned earlier, we are shifting our production operations away from China to our domestic facility. With this change of production venue, we will face increased reliance on our domestic supply chain for raw materials and components parts. We expect this reliance to continue to increase as our domestic production output increases. Any disruption in our suppliers' operations or timely availability of shipments from our third-party freight carriers could disrupt our ability to provide product to our customers in a timely manner, which could materially and adversely affect our results of operations and cash flows.

 Inflationary Price Pressures and Uncertain Availability of Commodities, Raw Materials, Utilities, Labor or Other Inputs Used by us and our Suppliers, or Instability in Logistics and Related Costs, Could Negatively Impact our Profitability

 Increases in the price of commodities, raw materials, utilities, labor or other inputs that we or our suppliers use in manufacturing and supplying products, components and parts, along with logistics and other related costs, may lead to higher production and shipping costs for our products, parts, and components. Further, increasing global demand for, and uncertain supply of, such materials could disrupt our or our suppliers' ability to obtain such materials in a timely manner to meet our supply needs and/or could lead to increased costs. A material increase in the cost of inputs to our production could lead to higher costs for our products and could negatively impact our operating results. The full impact of greater domestic production on our sourcing materials through our supply chain is not yet known and difficult to estimate. We expect that as we increase our materials acquisition levels for domestic production, we will be able to achieve economies of scale and greater volume-purchasing agreements with our suppliers, but there is no guarantee such benefits will materialize.

 Vaccine Hesitancy Could Impact Demand

 Overall demand may be affected by public sentiment and acceptance of the safety and efficacy of vaccinations. While some products in our catalog of products are unrelated to the administration of vaccines, changes in the acceptance of vaccinations could have a material impact on our business.

 We Face Inherent Product Liability Risks
 As a manufacturer and provider of safety needle products, we face an inherent business risk of exposure to product liability claims. Additionally, our success depends on the quality, reliability, and safety of our products and defects in our products could damage our reputation. If a product liability claim is made and damages are in excess of our product liability coverage, our competitive position could be weakened by the amount of money we could be required to pay to compensate those injured by our products. In the event of a recall, we have recall insurance.
 As disclosed in a Current Report on Form 8-K on February 16, 2024, we initiated a voluntary recall on February 5, 2024 of our EasyPoint Needle lot number K220402 which was shipped within the U.S. between July 20, 2022 and September 20, 2023. The recall was due to the possible detachment of the needle cannula from the needle holder, which could result in serious injury. The possible defect increases our risk of liability in connection with those units. Since the initiation of the voluntary recall, all reasonable efforts have been made to remove EasyPoint Needle lot K220402 from the market in accordance with the recall strategy. We believe the recall is complete and we have requested termination of the voluntary recall from the FDA. The Medical Devices and Radiological Health Risk Mitigation and Response Branch has: confirmed our request for termination, notified us that the division is currently experiencing a severe backlog of termination requests which are being processed in the order they are received and informed us that once the termination process begins, they will follow up with us concerning any additional questions they may have.
 Our Business May Be Affected by Changes in the Health Care Regulatory Environment
 In the U.S. and internationally, government authorities may enact changes in regulatory requirements, reform existing reimbursement programs, and/or make changes to patient access to health care, all of which could adversely affect the demand for our products and/or put downward pressure on our prices. Future healthcare rulemaking could affect our business. We cannot predict the timing or impact of any future rulemaking or changes in the law.
 We May Experience Losses in Our Investment Account
 Our investment portfolio is subject to market risk. As a result, the value and liquidity of our cash equivalents and marketable securities could fluctuate substantially. Likewise, our other income and expenses could vary materially depending on gains or losses realized on the sale or exchange of investments and other factors. Increased volatility in the financial markets and overall economic uncertainty could increase the risk that actual amounts realized on our investments may differ from the fair values currently assigned to them. Because 25.1% of our total assets are invested in the market, fluctuations in market values could have a material adverse impact on our business, financial condition, results of operations, or cash flows.
 Health Crises Could Have an Adverse Effect on Our Business
 In any future health crisis, we may elect or be required to close temporarily which would result in a disruption in our activities and operations. Our supply chain, including transportation channels, may be impacted by any such restrictions as well. Any such disruption could impact our sales and operating results.
 Widespread health crises also negatively affect economies which could affect demand for our products. In the event of a resurgence of COVID-19 or in the case of any future pandemic, there is no guarantee that revenues from syringes needed for vaccines would offset the effects to our business of a global economic decline.

 Travel and import restrictions may also disrupt our ability to manufacture or distribute our products. Any import or export or other cargo restrictions related to our products or the raw materials used to manufacture our products could restrict our ability to manufacture and ship products and harm our business, financial condition, and results of operations.
 Our key personnel and other employees could be affected by COVID-19 or any future pandemic, which could affect our ability to operate efficiently.
 Disruption of Critical Information Systems or Material Breaches in the Security of Our Systems Could Harm Our Business, Customer Relations, and Financial Condition
 Information technology helps us operate efficiently, interface with customers and suppliers, maintain financial accuracy and efficiency, and accurately produce our financial statements. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology infrastructure, we could be subject to transaction errors, processing inefficiencies, the loss of customers, business disruptions, or the loss of or damage to intellectual property through security breach. If our data management systems do not effectively collect, store, process, and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies, or human error, our ability to effectively plan, forecast, and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our financial condition, results of operations, cash flows, and the timeliness with which we report our internal and external operating results. Third parties may attempt to fraudulently induce employees or customers into giving away sensitive information, which may in turn be used to access our information technology systems. In addition, unauthorized persons may attempt to hack into our systems to obtain our confidential or proprietary information or confidential information we hold on behalf of third parties. If the unauthorized persons successfully hack into or interfere with our system, we may experience a negative impact to our business and reputation. We have programs in place to detect, contain, and respond to data security incidents, and we make ongoing improvements to our systems in order to minimize vulnerabilities, in accordance with industry and regulatory standards. However, we may not be able to anticipate and prevent these intrusions or mitigate them when and if they occur. We also rely on external vendors to supply and/or support certain aspects of our information technology systems. The systems of these external vendors may contain defects in design or manufacture or other problems that could unexpectedly compromise information security of our own systems, and we are dependent on these third parties to deploy appropriate security programs to protect their systems. It is possible for such vulnerabilities to remain undetected for an extended period, including several years or longer. The costs to us to eliminate or alleviate network security problems, bugs, viruses, worms, ransomware and other malicious software programs, and security vulnerabilities could be significant. Our efforts to address these problems may not be successful and could result in unexpected interruptions, delays, cessation of service, and harm to our business operations. Depending on the type of breach, we could also be exposed to a risk of loss or litigation and potential liability, which could have a material adverse impact on our business, financial condition, results of operations, or cash flows.
 Illegal Distribution and Sale by Third Parties of Counterfeit Versions of Our Products Could Have a Negative Impact
 Third parties may illegally distribute and sell counterfeit versions of our products which do not meet our rigorous manufacturing and testing standards. Our reputation and business could suffer harm as a result. In addition, diversion of products into other channels may result in reduced revenues.
 General Risk Factors
 We face risk factors common to other U.S. businesses. We could be subject to complex and costly regulation. Our business could suffer if we or our suppliers encounter manufacturing problems or disruptions to transportation channels. We could be subject to risks associated with doing business outside of the U.S, including risks associated with global economic, regulatory, or political changes, or health crises. Current or worsening economic conditions may adversely affect our business and financial condition.

 Item 1B. Unresolved Staff Comments.
 Not applicable and none.

 Item 1C. Cybersecurity

 We prioritize cybersecurity throughout our operations to protect sensitive data, ensure device integrity, and maintain business continuity. Our strategy is built on a layered approach encompassing proactive risk assessments, vulnerability management, data security, device security, employee training, and incident response. We have a documented incident response plan outlining steps for detection, containment, eradication, and recovery from cyberattacks. We conduct regular incident response drills to ensure preparedness. We use threat intelligence feeds and industry reports to stay informed about evolving cyber threats targeting the medical manufacturing industry. We conduct annual comprehensive risk assessments using industry-standard methodologies and tailored questionnaires for medical manufacturing risks. We continuously monitor system logs and security alerts for suspicious activity indicative of potential attacks. We track and prioritize identified risks based on a risk scoring system considering factors like data sensitivity and operational disruption. We implement multi-factor authentication for all remote access and privileged accounts. We segment our network to isolate critical systems holding personal identifying information, corporate data, and operational data. We encrypt sensitive data at rest and in transit using industry-standard algorithms. We regularly patch vulnerabilities in our systems based on severity and potential exploitability. We have strict access controls in place, granting privilege access based on job roles and responsibilities. We continuously monitor network activity for anomalies and suspicious behavior.
 Cybersecurity risks are integrated into our enterprise risk management framework and considered alongside other operational and financial risks during decision-making processes. The Information Security Officer (ISO) reports directly to the Chief Financial Officer (CFO) and regularly briefs the executive team on cybersecurity risks and mitigation strategies. We engage independent cybersecurity firms to conduct penetration testing, vulnerability assessments, and security audits of our IT and OT infrastructure. We also use external expertise for incident response support and regulatory compliance guidance. We conduct thorough cybersecurity risk assessments of all third-party vendors before onboarding, evaluating their security controls, data handling practices, and incident response capabilities. We require vendors to sign contracts that mandate adherence to specific cybersecurity standards and data privacy regulations. We conduct ongoing monitoring of vendor security posture and require them to promptly report any security incidents.
 The Board of Directors oversees the overall cybersecurity risk management program and holds management accountable for its effectiveness. The Board receives regular briefings on cybersecurity risks and mitigation strategies. The ISO regularly reports to the Board and executive management on the status of the cybersecurity risk management program, including key risks, mitigation strategies, and incident reports. The program is reviewed periodically to assess its effectiveness and identify areas for improvement. Management's role is to assist the Board in identifying and considering material cybersecurity risks, ensure implementation of management-level and employee-level cybersecurity practices and training, and provide the Board with regular reports regarding any cybersecurity attacks or vulnerabilities. As of the date of this Annual Report on Form 10-K, our assessment indicates that cybersecurity incidents have not had a material effect on our operations or financial condition and, based on the current knowledge of Management, are not likely to materially affect us.
 The ISO handles developing, implementing, and maintaining the cybersecurity risk management program and reports directly to the CFO who has the authority to allocate resources and make decisions related to cybersecurity. A cross-functional committee composed of representatives from Management, IT, legal, compliance, operations and other relevant departments aids the ISO in managing cyber risks and developing program initiatives. Business unit and departmental leaders are responsible for implementing cybersecurity controls within their areas of responsibility and reporting potential risks to the ISO. Regular cybersecurity awareness training is provided to all employees to educate them on cyber threats, best practices, and reporting procedures. Management and IT personnel receive additional training on specific security concepts and risk management techniques. We are committed to continuous improvement of our cybersecurity risk management program. We actively monitor industry best practices and adapt our program to address evolving threats and risks.

 Item 2. Properties.
 Our headquarters are located at 511 Lobo Lane, on 35 acres, which we own, overlooking Lake Lewisville in Little Elm, Texas. The headquarters are in good condition and houses our administrative offices and manufacturing facility. The manufacturing facility produced approximately 16.1% of the units that were manufactured in 2024. As a result of recent expansions, we have significant additional domestic production capacity for some of our products, primarily vaccination syringes and needles associated with the TIA. However, we do not currently have the necessary equipment to produce every product we offer, and may continue to rely on our international manufacturers to supply those products, incurring the cost of import tariffs.
 A loan in the original principal amount of approximately $4,210,000 is secured by our land and buildings. See Note 8 to our financial statements for more information.
 In the opinion of Management, the property and equipment are suitable for their intended use and are adequately covered by an insurance policy.
 Item 3. Legal Proceedings.
 Please refer to Note 10 to the financial statements for a complete description of all legal proceedings.

 Item 4. Mine Safety Disclosures.
 Not applicable.

 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities.
 MARKET INFORMATION
 Our Common Stock has been listed on the NYSE American (or its predecessor entities) under the symbol "RVP" since May 4, 2001. The closing market price on March 10, 2025 was $0.72 per share.
 SHAREHOLDERS
 As of March 10, 2025, there were 34,024,304 shares of Common Stock issued, of which 4,087,145 shares were held in treasury. There were 143 shareholders of record, not including Cede & Co. participants or beneficial owners thereof.
 DIVIDENDS
 We have not ever declared or paid any dividends on the Common Stock. We have no current plans to pay any cash dividends on the Common Stock.
 EQUITY COMPENSATION PLAN INFORMATION
 The following table sets forth information relating to our equity compensation plans as of December 31, 2024:

 Equity Compensation Plan Information

 Weighted

 Number of securities

 average exercise

 remaining available for

 Number of securities

 price of

 future issuance under

 to be issued upon

 outstanding

 equity compensation

 exercise of

 options,

 plans (excluding

 outstanding options,

 warrants and

 securities reflected in

 warrants and rights

 rights

 column(a))

 Plan category

 (a)

 (b)

 (c)

 Equity compensation plans approved by security holders

 145,950

 $

 2.05

 2,000,000

 Total

 145,950

 $

 2.05

 2,000,000

 STOCK PERFORMANCE GRAPH
 The following graph compares the cumulative total return for our Common Stock (RVP) from December 31, 2019 to December 31, 2024, to the total returns for the Russell Microcap and the Dow Jones U.S. Select Medical Equipment Index (DJSMDQ). The graph assumes an investment of $100 in the aforementioned equities as of December 31, 2019, and that all dividends are reinvested.

 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 Not applicable.

 PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
 None.

 Item 6. Reserved.
 Not required.

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation.
 FORWARD-LOOKING STATEMENT WARNING
 Certain statements included by reference in this filing containing the words "could," "may," "believes," "anticipates," "intends," "expects," and similar such words constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Any forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, material changes in demand, tariffs, our ability to maintain liquidity, our maintenance of patent protection, our ability to maintain favorable third party manufacturing and supplier arrangements and relationships, foreign trade risk, our ability to access the market, production costs, the impact of larger market players in providing devices to the safety market, and other factors referenced in Item 1A. Risk Factors. Given these uncertainties, undue reliance should not be placed on forward-looking statements.
 Overview
 We have been manufacturing and marketing our products since 1997. Syringes comprised 68.5% of our sales in 2024. EasyPoint products accounted for 27.1% of sales in 2024 and other products, including our IV safety catheter and blood collection products were 4.5% of our total product sales in 2024.
 On September 13, 2024, the Office of the U.S. Trade Representative ("USTR") revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 of the Trade Act of 1974. Among those products included were syringes and needles, at a rate of 100%. Additionally, effective February 4th and March 4th of 2025, tariffs on Chinese imports were increased by an aggregate total of 20%. The increase of 20% applied not only to syringes and needles, but to other products we import from China. While we have manufacturing capabilities to manufacture most of the products we currently sell domestically, some of our products are sourced exclusively from China. As previously noted, 83.9% of the products the Company obtained in 2024 were purchased from our manufacturers in China, most of which are impacted by the tariffs. The adjusted tariffs were effective on September 27, 2024. Tariffs are expected to have a material impact to our results of operations and financial position. Approximately $1.6 million was spent on tariff expenses from September - December 2024 when the tariff rate was 100% on syringes and needles imported from China. From January 1 to March 21, 2025 under a system of increasing tariffs, we have paid a total of approximately $951,000 on tariff expenses. We are working to lessen the financial impact of the tariffs, including shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint needles to our domestic manufacturing facility, but while these actions would decrease tariff expenses, they have led to an annualized estimated $3.8 million increase in compensation and benefits expense as we have hired additional manufacturing personnel.
 We have recently adapted some equipment to increase our domestic manufacturing capabilities. The adaptations to existing equipment will allow us to produce 0.5 mL syringes domestically. Once operational, we will no longer rely on imports for these products, and they will no longer be affected by tariff costs. We expect that commercial quantities will be available in the second half of 2025.
 Certain products must be purchased from third party suppliers as we do not currently have the machinery to manufacture our entire product line in our U.S. facility. When equipment was added to our U.S. facility pursuant to the TIA, it was strictly for product lines typically used in the administration of vaccines, as required by the TIA.
 Our products have been and continue to be distributed nationally and internationally through numerous distributors. Some of our popular syringe products provide low dead-space. Low dead-space syringes reduce residual medication remaining in the syringe after the dose has been administered. In some instances, the low dead-space allows for additional doses of medication to be obtained from the vials.
 In 2020 and 2021, we were awarded significant orders and contracts by the U.S. government for safety syringes for COVID-19 vaccination efforts. From 2020 through the first quarter of 2022, the U.S. government was a significant customer. We cannot predict whether any future U.S. government orders may occur.

 Recent additions of manufacturing equipment and facilities under the 2020 TIA have increased our production capacity and our overhead costs. Under the TIA and its successor agreement, until June 30, 2030 we must continue to abide by ongoing terms which include maintenance of equipment, availability of capacity, and US government preference in the event of a public health emergency.
 The U.S. government orders as well as the TIA are material events particular to the COVID-19 pandemic and are not indicative of future operations.
 Over the past several years, we have experienced certain cost increases in raw materials. Those costs primarily affected our domestic manufacturing because the finished goods we purchased from China (being 83.9% of our products in 2024) were subject to a long-term fixed price contract. Sensitivity to cost fluctuations may become more pronounced as we transition away from production under such a fixed price contract. Other factors that could affect our unit costs include tariffs, supplier cost increases, increases in workforce costs associated with increased domestic production, and changing production volumes. Increases in costs may not be recoverable through price increases of our products.

 We believe domestic customers have retained products provided for vaccination purposes in inventory. Customers have reported that demand was diminished due to their remaining syringe inventory. It is difficult to estimate how much of the remaining inventory might still remain in the market.
 As detailed in Note 4 to the financial statements, we held $40.3 million in debt and equity securities as of December 31, 2024, which represented 25.1% of our total assets. During 2024, we liquidated $6 million in mutual funds for operating purposes.
 Historically, unit sales have increased during the flu season. From 2020-2022, seasonal effects of the flu season on our revenues were less impactful due to the dramatic increase in sales attributable to COVID-19 vaccinations. Seasonal trends for syringe sales may now be following pre-pandemic patterns. Additionally, there may be more demand for EasyPoint products during the flu season, particularly in the retail pharmacy market. Overall demand may be affected by public sentiment and acceptance of the safety and efficacy of vaccinations. While some products in our catalog of products are unrelated to the administration of vaccines, changes in the acceptance of vaccinations could have a material impact on our business.
 A material portion of our net losses for the year ended December 31, 2024 is comprised of the approximately $8.4 million change in valuation allowance which occurred in the second quarter of 2024 on the deferred tax asset which is included as a provision for income taxes on the Condensed Statements of Operations. The devaluation of the deferred tax asset was related to our determination that, based on current information, it was more likely than not that we wouldn't be in a position to use loss carryforwards against future taxable net income based on a variety of factors and accounting guidelines. The announced implementation of tariffs on imported syringes from China was one of the factors considered in this determination. Our assessment of the valuation allowance has not changed since the second quarter.
 In 1995, we entered into a license agreement with Thomas J. Shaw for the exclusive right to manufacture, market, and distribute products utilizing his patented automated retraction technology and other patented technology. This technology is the subject of various patents and patent applications owned by Mr. Shaw. The license agreement generally provides for quarterly payments of a 5% royalty fee on gross sales of products subject to the license and he receives fifty percent (50%) of the royalties paid to us by certain sublicensees of the technology subject to the license.
 Included in net sales for 2024 is $189 thousand in licensing fees recorded under a sublicensing agreement with one of our Chinese manufacturers. Under the terms of our licensing agreement with Mr. Shaw, he is entitled to receive 50% of this amount, which is recorded as royalty expense to shareholder in total cost of sales for the year.
 RESULTS OF OPERATIONS
 The following discussion may contain trend information and other forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ materially from our historical results of operations

 and those discussed in any forward-looking statements. All period references are to our fiscal years ended December 31, 2024 and 2023. Dollar amounts have been rounded for ease of reading.
 Comparison of Year Ended
 December 31, 2024 and Year Ended December 31, 2023
 Domestic sales accounted for 88.9% and 79.4% of the revenues in 2024 and 2023, respectively. Domestic revenues decreased 15.1% principally due to a decrease in the average selling price, largely due to higher sales of our EasyPoint needles which typically have a lower average selling price combined with higher transactional and order fulfillment costs with our distributors. Domestic unit sales decreased 4.3%. Domestic unit sales were 87.7% of total unit sales for 2024. International revenues decreased 59.1% predominantly due to fewer international vaccination-related sales. Overall unit sales decreased 19.1% and our overall revenues decreased by 24.2%. There is uncertainty as to the timing of future international orders.
 Cost of manufactured product remained consistent. However, the decrease in revenue did not result in a corresponding decrease in costs. This is primarily driven by a decrease in the volume of units sold, partially offset by higher period costs associated with increased domestic production activities. Royalty expense decreased 18.8% due to the associated decrease in gross sales and decrease in royalties from sublicenses.
 Tariffs are expected to materially increase our costs in future periods. Approximately $1.6 million was spent on tariff expenses from September - December 2024. These costs are included in Cost of manufactured product.
 As a result of the above, gross profit margins decreased from 20.9% in 2023 to (3.1)% in 2024.
 Operating expenses decreased slightly, primarily due to a reduction in property tax expense resulting from newly enacted property tax exemption legislation related to medical device property. This decrease was partially offset by increases in litigation costs, wages, and sales and marketing expenses.
 The loss from operations was $21.1 million as compared to a loss from operations of $11.5 million in 2023. The increased loss was due to lower gross profit for the year.
 The unrealized gain on debt and equity securities was $10.8 million due to the increased market values of those securities.
 The provision for income taxes was $8.4 million as compared to a benefit for income taxes of $1.9 million for 2023. The difference is primarily related to fully reserving our deferred tax asset in the second quarter of 2024. For a detailed description of the determination and components of calculating the provision, please refer to Note 11 of the financial statements.
 A comparison of the results of operations for the years ended December 31, 2023 and December 31, 2022 is omitted from this discussion. Such comparison was included in our Annual Report on Form 10-K filed with the SEC on March 29, 2024 in Item 7 of Part II thereof.
 LIQUIDITY AND CAPITAL RESOURCES
 Cash flow used by operations was $11.6 million in 2024 due to a number of factors. Aside from the various reconciling items used in determining the overall use of cash, our net loss for the year was the predominant factor. We recognized approximately $5.9 million in other income from the TIA, offset by an increase of $8.4 million in valuation allowance related to deferred tax assets which is material to the adjustments to total cash flow from operations. Changes in working capital also impacted cash flows from operating activities. Accounts receivable decreased by $2.0 million, inventories increased by $1.6 million, and accounts payable decreased by $488 thousand.

 Cash flow from investing activities was $3.7 million in 2024 due primarily to the net sale of debt and equity securities, offset by $1.4 million for the purchase of property, plant, and equipment. The $6 million obtained as a result of the sale of securities was used to fund operating activities during the year.
 Cash used by financing activities was $535 thousand for 2024. This was primarily due to repayments of long-term debt and payment of preferred stock dividends.
 We have historically funded operations primarily from the proceeds from revenues, private placements, litigation settlements, and loans. We may fund operations going forward from revenues, cash reserves, and investments in trading securities should the need to access those funds arise.
 The imposition of tariffs on our products will have a material effect on our operating results and liquidity. Additional capital improvements and increases to our manufacturing workforce will also increase expenses in the near-term as a result of the tariffs and our expected increase in domestic manufacturing. The conversion of existing equipment to produce products which have never been produced domestically is expected to cost approximately $1 million. Those products accounted for roughly 10.5% of our overall domestic unit sales and 16.6% of our domestic syringe unit sales. The overall impact of additional workforce needed to produce these and other products is an increase of approximately $3.8 million on an annual basis.
 Margins
 The mix of domestic and international sales, along with product mix, affects the average sales price of our products. Generally, the higher the ratio of domestic sales to international sales, the higher the average sales price will be. Additionally, product mix plays a role, with syringe sales typically having higher average selling prices and gross profit margins than our other product lines. Some international sales of our products are shipped directly from China to the customer. The number of units produced by us versus manufactured in China can have a significant effect on the carrying costs of Inventory as well as Cost of sales. Generally, an overall increase in units sold can positively affect our margins. The cost of raw materials used in manufacturing, transportation costs, and the impact of tariffs can also significantly affect our margins.
 Our margins have experienced significant fluctuations over the past two years. Most recently in 2024, our margins have faced negative pressure from numerous factors. The tariffs enacted in 2024 have had a direct negative impact on products we import from China in 2024 and to date in 2025. In reaction to the tariffs, we have acted to increase our domestic production and reduce, to the extent possible, our reliance on imports. While we believe these efforts will enable us to avoid some of the impact of the tariffs, we will be forced to import the products we are unable to produce in the U.S. The decline in units sold in 2024 has also had a negative impact on our margins. As we work to increase our domestic production and achieve manufacturing efficiencies, we will continue to work to minimize our reliance on imported products.
 Cash Requirements
 We believe we will have adequate means to meet our short-term needs to fund operations for at least 12 months from the date of issuance of the financial statements. Besides cash reserves and expected income from operations, we also have access to our investments which may be liquidated in the event that we need to access the funds for operations. Expected short-term uses of cash include payroll and benefits, royalty expense, inventory purchases, tariffs, contractual obligations, payment of income taxes, quarterly preferred stock dividends, and other operational priorities. Our year-end liabilities are detailed in our financial statements, including Notes 7 and 8 to the financial statements. We believe we will have adequate means to meet our currently foreseeable long-term liquidity needs, although the new tariffs and our costs related to an increase in domestic manufacturing will increase our expenses materially. For the next 1-3 years, we believe our liquidity will decline materially, but we expect that we may be able to satisfy our long-term cash requirements using a combination of cash and liquidation of our equity investments. If cash needs cannot be met using existing cash and investments, management would reduce operational costs. In the event that the foregoing is insufficient, we may liquidate certain assets.

 Capital Resources
 We expect to spend approximately $1 million over the next few months using existing cash reserves to convert a portion of our domestic equipment to align to our plan to produce more units at our U.S. facility. While additional equipment expenditures may be necessary in the future, this near-term equipment conversion is expected to be completed by the second quarter of 2025.
 CRITICAL ACCOUNTING ESTIMATES
 We are responsible for developing estimates for amounts reported as assets and liabilities, and revenues and expenses in conformity with U.S. generally accepted accounting principles ("GAAP"). Those estimates require that we develop assumptions of future events based on past experience and expectations of economic factors. Among the more critical estimates management makes is the estimate for customer rebates. The amount reported as a contractual allowance for rebates involves examination of past historical trends related to our sales to distributors and the related credits issued once our distributors have satisfied their contractual obligations. The estimate includes consideration of historical redemption rates, discount rates, a combination of estimated distributor inventories based on tracking information provided by the distributors or if known, inventory turnover rates. The establishment of a liability for future claims of rebates against sales in the current period requires that we have an understanding of the relevant sales with respect to product categories, sales distribution channels, and the likelihood of contractual obligations being satisfied. We examine the results of estimates against actual results historically and use the determination to further develop our basis for assumptions in future periods, as well as the accuracy of past estimates. Based on distributors' purchasing and claiming rebates practices, we do not expect significant changes to the current inputs and assumption used in the estimate calculations. While we believe that we have sufficient historical data, and a firm basis for establishing reserves for contractual obligations, there is an inherent risk that our estimates and the underlying assumptions may not reflect actual future results. In the event that these estimates and/or assumptions are incorrect, adjustments to our reserves may have a material impact on future results. As of December 31, 2024, we estimate that the total potential future credits to be issued as a result of prior purchases which have not yet been claimed is $2.1 million.

 Item 7A. Quantitative and Qualitative Disclosures about Market Risk.
 Not applicable to smaller reporting companies.

 Item 8. Financial Statements and Supplementary Data.
 FINANCIAL STATEMENTS AND
 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 DECEMBER 31, 2024 and 2023

 INDEX TO FINANCIAL STATEMENTS

 Page

 Report of Independent Registered Public Accounting Firm ( Moss Adams LLP, Dallas, TX, PCAOB ID No. 659)

 Financial Statements:

 Balance Sheets as of December 31, 2024 and 2023

 Statements of Operations for the years ended December 31, 2024, 2023, and 2022

 Statements of Changes in Stockholders' Equity for the years ended December 31, 2024, 2023, and 2022

 Statements of Cash Flows for the years ended December 31, 2024, 2023, and 2022

 Notes to Financial Statements

 Financial Statement Schedule:

 Schedule II: Schedule of Valuation and Qualifying Accounts for the years ended December 31, 2024, 2023, and 2022

 Report of Independent Registered Public Accounting Firm
 To the Stockholders and the Board of Directors of
 Retractable Technologies, Inc.
 Opinion on the Financial Statements
 We have audited the accompanying balance sheets of Retractable Technologies, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations, changes in stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and schedules (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.
 Basis for Opinion
 These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
 Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 Critical Audit Matter
 The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
 Revenue Recognition - Rebates
 As described in Note 2 to the financial statements, the Company's estimated contractual pricing allowances for rebates at December 31, 2024 is $2.1 million. The Company recognizes revenue when it has satisfied all performance obligations to the customer. Under certain contracts, revenue is recorded on the basis of sales price to distributors, less contractual pricing allowances. Contractual pricing allowances consist of: (i) rebates granted to distributors who provide tracking reports, which show, among other things, the facility that purchased the products, and (ii) a provision for estimated contractual pricing allowances for products for which the Company has not received tracking reports. Once rebates are issued, they are applied against the customer's receivable balance. The amount reported as a contractual allowance for rebates involves

 examination of historical trends related to sales to the Company's customers and the related credits issued once contractual obligations of the customers have been met. The establishment of a contractual pricing allowance for rebates requires that the Company has an understanding of the relevant sales with respect to product categories, sales distribution channels, and the likelihood of contractual obligations being satisfied.

 We identified management's estimates of contractual pricing allowances for rebates as a critical audit matter. Auditing the estimated contractual pricing allowances at period end involved significant audit effort, as well as especially challenging and subjective auditor judgment when performing audit procedures and evaluating the results of those procedures.

 The primary procedures we performed to address this critical audit matter included:

 Testing management's process for determining the estimates of contractual pricing allowances for rebates by performing the following procedures:

 o
 Obtaining an understanding and evaluating the methodology used by management to develop its estimate.

 o
 Testing management's analysis for clerical accuracy.

 o
 Testing the completeness, accuracy, and reliability of underlying data used by management in the estimate.

 o
 Evaluating the reasonableness of significant assumptions used by management.

 Analytically comparing the recorded balance to a predicted balance based on historical information and trends.

 Evaluating rebate activity occurring after the period.

 /s/ Moss Adams LLP
 Dallas, Texas
 We have served as the Company's auditor since 2016.

 BALANCE SHEETS

 ASSETS

 Current assets:

 Cash and cash equivalents

 $

 4,235,388

 $

 12,667,550

 Accounts receivable, net

 7,786,697

 10,671,721

 Investments in debt and equity securities, at fair value

 40,328,308

 34,621,213

 Inventories

 19,189,753

 17,581,368

 Income taxes receivable

 978,851

 1,155,077

 Other current assets

 753,062

 952,668

 Total current assets

 73,272,059

 77,649,597

 Property, plant, and equipment, net

 87,348,518

 93,478,521

 Deferred tax asset

 —

 8,392,030

 Other assets

 103,625

 152,064

 Total assets

 $

 160,724,202

 $

 179,672,212

 LIABILITIES AND STOCKHOLDERS' EQUITY

 Current liabilities:

 Accounts payable

 $

 4,290,588

 $

 4,779,035

 Current portion of long-term debt

 332,480

 303,991

 Accrued compensation

 1,073,357

 865,105

 Dividends payable

 1,417,437

 1,417,437

 Accrued royalties to shareholder

 789,358

 1,376,555

 Other accrued liabilities

 873,254

 630,571

 Income taxes payable

 4,442

 4,802

 Total current liabilities

 8,780,916

 9,377,496

 Other long-term liabilities

 63,872,553

 69,773,538

 Long-term debt, net of current maturities

 900,042

 1,233,519

 Total liabilities

 73,553,511

 80,384,553

 Commitments and contingencies – see Note 10

 Stockholders' equity:

 Preferred stock, $ 1 par value:

 Class B; authorized: 5,000,000 shares

 Series II, Class B convertible; 156,200 shares outstanding at December 31, 2024 and 2023 (liquidation preference of $ 1,952,500)

 Series III, Class B convertible; 74,245 shares outstanding at December 31, 2024 and 2023 (liquidation preference of $ 928,063)

 Common Stock, no par value; authorized: 100,000,000 shares; 34,024,304 shares issued and 29,937,159 shares outstanding at December 31, 2024 and 2023

 —

 —

 Additional paid-in capital

 73,160,333

 73,160,333

 Retained earnings

 26,668,591

 38,785,559

 Common stock in treasury – at cost ( 4,087,145 shares at December 31, 2024 and 2023)

 Total stockholders' equity

 87,170,691

 99,287,659

 Total liabilities and stockholders' equity

 $

 160,724,202

 $

 179,672,212

 See accompanying notes to financial statements

 STATEMENTS OF OPERATIONS

 2024

 2023

 2022

 Sales, net

 $

 33,049,533

 $

 43,596,926

 $

 94,818,938

 Cost of sales:

 Cost of manufactured product

 31,158,190

 30,894,985

 60,628,548

 Royalty expense to shareholder

 2,919,519

 3,594,130

 5,937,107

 Total cost of sales

 34,077,709

 34,489,115

 66,565,655

 Gross profit (loss)

 ( 1,028,176)

 9,107,811

 28,253,283

 Operating expenses:

 Sales and marketing

 5,848,164

 5,706,483

 4,544,052

 Research and development

 673,944

 581,172

 525,727

 General and administrative

 13,555,283

 14,308,365

 24,036,480

 Total operating expenses

 20,077,391

 20,596,020

 29,106,259

 Loss from operations

 ( 21,105,567)

 ( 11,488,209)

 ( 852,976)

 Other income - TIA

 5,900,985

 6,223,891

 3,832,747

 Unrealized gain (loss) on debt and equity securities

 10,806,320

 ( 10,521,166)

 2,343,359

 Gain on sale of equity securities

 —

 5,574,792

 —

 Interest and other income

 1,000,428

 1,446,661

 9,948

 Interest expense

 ( 122,500)

 ( 152,166)

 ( 170,651)

 Income (loss) before income taxes

 ( 3,520,334)

 ( 8,916,197)

 5,162,427

 Provision (benefit) for income taxes

 8,366,190

 ( 1,905,161)

 83,870

 Net income (loss)

 Preferred Stock dividend requirements

 ( 230,444)

 ( 231,946)

 ( 232,444)

 Net income (loss) applicable to common shareholders

 $

 ( 12,116,968)

 $

 ( 7,242,982)

 $

 4,846,113

 Basic earnings (loss) per share

 $

 ( 0.40)

 $

 ( 0.24)

 $

 0.15

 Diluted earnings (loss) per share

 $

 ( 0.40)

 $

 ( 0.24)

 $

 0.15

 Weighted average common shares outstanding:

 Basic

 32,896,348

 Diluted

 32,961,945

 See accompanying notes to financial statements

 STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

 Series II Class B

 Series III Class B

 Common

 Additional Paid-

 Retained Earnings

 Treasury

 Amount

 Amount

 Amount

 in Capital

 (Accumulated Deficit)

 Stock

 Total

 Balance as of December 31, 2021

 76,245

 76,245

 33,484,935

 —

 63,024,888

 41,182,429

 ( 5,270,501)

 99,169,261

 Stock Option Exercises

 —

 —

 —

 —

 11,200

 —

 13,800

 —

 —

 13,800

 Dividends

 —

 —

 —

 —

 —

 —

 —

 ( 232,445)

 —

 ( 232,445)

 Stock Option Compensation

 —

 —

 —

 —

 —

 —

 10,125,813

 —

 —

 10,125,813

 Repurchase of Common Stock - at cost

 —

 —

 —

 —

 ( 3,558,976)

 —

 —

 —

 ( 7,618,177)

 ( 7,618,177)

 Net income

 —

 —

 —

 —

 —

 —

 —

 —

 Balance as of December 31, 2022

 76,245

 76,245

 —

 73,164,501

 46,028,541

 106,536,809

 Redemption

 —

 —

 ( 2,000)

 ( 2,000)

 —

 —

 ( 4,168)

 —

 —

 ( 6,168)

 Dividends

 —

 —

 —

 —

 —

 —

 —

 ( 231,946)

 —

 ( 231,946)

 Net loss

 —

 —

 —

 —

 —

 —

 —

 —

 Balance as of December 31, 2023

 —

 73,160,333

 38,785,559

 99,287,659

 Dividends

 —

 —

 —

 —

 —

 —

 —

 ( 230,444)

 —

 ( 230,444)

 Net loss

 —

 —

 —

 —

 —

 —

 —

 —

 Balance as of December 31, 2024

 $

 $

 $

 —

 $

 73,160,333

 $

 26,668,591

 $

 $

 87,170,691

 See accompanying notes to financial statements

 STATEMENTS OF CASH FLOWS

 2024

 2023

 2022

 Cash flows from operating activities

 Net income (loss)

 $

 $

 $

 Adjustments to reconcile net income (loss) to net cash from (used) operating activities:

 Depreciation and amortization

 7,569,946

 7,527,227

 4,602,961

 Net unrealized (gain) loss on investments

 ( 10,806,320)

 10,521,166

 ( 2,343,359)

 Realized gain (loss) on investments

 —

 ( 5,574,792)

 327,926

 Accreted interest

 —

 9,157

 60,115

 Bond amortization

 ( 1,024)

 ( 970)

 ( 159)

 Deferred taxes

 8,392,030

 ( 1,873,367)

 7,347,171

 Provision for credit losses

 571,682

 626,940

 322,991

 Share-based compensation

 —

 —

 10,125,813

 Net realizable value inventory adjustment

 —

 175,355

 —

 Other income - TIA

 ( 5,900,985)

 ( 6,223,891)

 ( 3,832,747)

 (Increase) decrease in operating assets:

 Accounts receivable

 2,313,342

 ( 6,463,542)

 29,701,396

 Inventories

 ( 1,608,385)

 2,927,445

 ( 94,249)

 Other current assets

 199,606

 313,848

 ( 564,496)

 Income taxes receivable

 176,226

 9,464,758

 ( 10,619,886)

 Other assets

 48,439

 32,460

 ( 178,850)

 Increase (decrease) in operating liabilities:

 Accounts payable

 ( 488,447)

 ( 1,625,890)

 ( 13,999,647)

 Accrued liabilities

 ( 136,262)

 ( 4,269,163)

 Income taxes payable

 ( 360)

 ( 58,827)

 ( 4,896,246)

 Net cash from (used) operating activities

 ( 11,557,036)

 2,766,848

 16,768,128

 Cash flows from investing activities

 Purchase of property, plant, and equipment

 ( 1,439,943)

 ( 852,979)

 ( 16,830,077)

 Purchase of debt and equity securities

 ( 899,750)

 ( 68,481,490)

 ( 18,135,191)

 Proceeds from the sales of debt and equity securities

 6,000,000

 58,572,186

 3,762,454

 Net cash from (used) investing activities

 3,660,307

 ( 10,762,283)

 ( 31,202,814)

 Cash flows from financing activities

 Repayments of long-term debt

 ( 304,988)

 ( 281,866)

 ( 283,933)

 Proceeds from Technology Investment Agreement (TIA)

 —

 2,563,229

 14,235,417

 Proceeds from the exercise of stock options

 —

 —

 13,800

 Payment of preferred stock repurchase payable

 —

 ( 1,101,110)

 ( 1,101,110)

 Payment of preferred stock dividends

 ( 230,445)

 ( 232,445)

 ( 252,879)

 Redemption of preferred stock

 —

 ( 6,168)

 —

 Repurchase of common stock

 —

 —

 ( 7,618,177)

 Net cash from (used) financing activities

 ( 535,433)

 941,640

 4,993,118

 Net decrease in cash and cash equivalents

 ( 8,432,162)

 ( 7,053,795)

 ( 9,441,568)

 Cash and cash equivalents at:

 Beginning of period

 12,667,550

 19,721,345

 29,162,913

 End of period

 $

 4,235,388

 $

 12,667,550

 $

 19,721,345

 Supplemental schedule of cash flow information:

 Interest paid

 $

 122,500

 $

 161,322

 $

 110,537

 Income taxes paid (received)

 $

 —

 $

 ( 9,747,329)

 $

 12,323,857

 Supplemental schedule of noncash investing and financing activities:

 Preferred dividends declared, not paid

 $

 57,611

 $

 57,611

 $

 58,111

 Amounts receivable under Technology Investment Agreement (TIA)

 $

 —

 $

 —

 $

 2,025,413

 Redemption price payable

 $

 6,000

 $

 6,000

 $

 6,000

 Preferred stock repurchase payable

 $

 —

 $

 —

 $

 1,091,953

 See accompanying notes to financial statements

 NOTES TO FINANCIAL STATEMENTS
 1. BUSINESS OF THE COMPANY AND BASIS OF PRESENTATION
 Business of the Company
 Retractable Technologies, Inc. (the "Company") was incorporated in Texas on May 9, 1994, and designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. The Company began to develop its manufacturing operations in 1995. The Company's manufacturing and administrative facilities are located in Little Elm, Texas. The Company's products are the VanishPoint 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; the small diameter tube adapter; the blood collection tube holder; the EasyPoint blood collection tube holder with needle; the allergy tray; the IV safety catheter; the Patient Safe syringes; the Patient Safe Luer Cap; the VanishPoint Blood Collection Set; and the EasyPoint needle, as well as a standard 3mL syringe packaged with an EasyPoint needle. The Company also sells VanishPoint autodisable syringes in the international market in addition to the Company's other products.

 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 Accounting estimates
 The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. The amount reported as a contractual allowance for rebates involves examination of past historical trends related to sales to customers and the related credits issued once contractual obligations of the customers have been met. The establishment of a liability for future claims of rebates against sales in the current period requires that the Company has an understanding of the relevant sales with respect to product categories, sales distribution channels, and the likelihood of contractual obligations being satisfied.
 Cash and cash equivalents
 For purposes of reporting cash flows, cash and cash equivalents include cash, money market accounts, and investments with original maturities of three months or less.
 Accounts receivable
 The Company records trade receivables when revenue is recognized. No product has been consigned to customers. The Company's allowance for credit losses is primarily determined by review of specific trade receivables based on historical collection rates and specific knowledge regarding the current creditworthiness of the customers. Those accounts that are doubtful of collection are included in the allowance. The Company considers historical experience, the current economic environment, customer credit ratings or bankruptcies, legal disputes, collections on past due amounts, pricing discrepancies, and reasonable and supportable forecasts to develop its allowance for credit losses. Management reviews these factors quarterly to determine if any adjustments are needed to the allowance. Trade receivables are charged off when there is certainty as to their being uncollectible. Trade receivables are considered delinquent when payment has not been made within contract terms. The allowance for credit losses was $ 668,124 and $ 890,541 as of December 31, 2024 and 2023, respectively.
 The Company requires certain customers to make a prepayment prior to beginning production or shipment of their order. Customers may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders. Such amounts are included in Other accrued liabilities on the Balance Sheets and are shown in Note 7, Other Accrued Liabilities.

 The Company records an allowance for estimated returns as a reduction to Accounts receivable and Gross sales. Historically, returns have been insignificant.
 Inventories
 Inventories are valued at the lower of cost or net realizable value, with cost being determined using actual average cost. The Company compares the average cost to the net realizable value and records the lower value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For the years ended December 31, 2024 and 2023, respectively, the Company recorded $ 0 and $ 101 thousand lower of cost or net realizable value inventory adjustment associated with the VanishPoint 3mL and EasyPoint needle product segments.
 Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories. Once inventory items are deemed to be either excess or obsolete, they are written down to their net realizable value.
 Investments in debt and equity securities
 The Company holds mutual funds, debt, and equity securities as investments. These assets are held as trading securities and are carried at fair value as of the date of the Balance Sheets. Net unrealized and realized gains or losses on these investments are reflected separately on the Statements of Operations. Realized gains or losses on investments are recognized using the specific identification method.
 Property, plant, and equipment
 Property, plant, and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to operations as incurred. Cost includes major expenditures for improvements and replacements which extend useful lives or increase capacity and interest costs associated with significant capital additions. Gains or losses from disposals are included in Interest and other income.
 The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:

 Production equipment

 3 to 13 years

 Office furniture and equipment

 3 to 10 years

 Buildings

 39 years

 Building improvements

 5 to 15 years

 Long-lived assets
 The Company assesses the recoverability of long-lived assets using an assessment of the estimated undiscounted future cash flows related to such assets. In the event that assets are found to be carried at amounts which are in excess of estimated gross future cash flows, the assets will be adjusted for impairment to a level commensurate with fair value determined using a discounted cash flow analysis or appraised values of the underlying assets.
 Fair value measurements
 For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets.

 For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model.
 Financial instruments
 The Company estimates the fair value of financial instruments through the use of public market prices, quotes from financial institutions, and other available information. Judgment is required in interpreting data to develop estimates of fair value and, accordingly, amounts are not necessarily indicative of the amounts that could be realized in a current market exchange. Short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on Management's estimates, equals their recorded values. Investments in debt and equity securities consist primarily of individual equity securities and mutual funds and are reported at their fair value based upon quoted prices in active markets. The fair value of long-term liabilities, based on Management's estimates, approximates their reported values.
 Concentration risks
 The Company's financial instruments exposed to concentrations of credit risk consist primarily of cash, cash equivalents, certificates of deposit, exchange-traded and closed-end funds, mutual funds, equity securities, and accounts receivable. Cash balances, some of which exceed federally insured limits, are maintained in financial institutions; however, Management believes the institutions are of high credit quality. The majority of accounts receivable are due from companies that are well-established entities. The Company assesses market risk in equity securities through consultation with its outside investment advisors. Management is responsible for directing investment activity based on current economic conditions. Management considers any exposure from concentrations of credit risks to be limited.
 The following table reflects our significant customers in 2024, 2023, and 2022:

 2024

 2023

 2022

 Number of significant customers

 Aggregate dollar amount of net sales to significant customers

 $

 17.8 million

 $

 25.9 million

 $

 66.4 million

 Percentage of net sales to significant customers

 53.8

 %

 61.3

 %

 70.0

 %

 The Company manufactures some of its products in Little Elm, Texas, as well as utilizing manufacturers in China. The Company obtained roughly 83.9 % of its products in 2024 from its Chinese manufacturers. Purchases from Chinese manufacturers aggregated 88.4 % and 91.6 % of products in 2023 and 2022, respectively. In the event that the Company becomes unable to purchase product from its Chinese manufacturers or produce those products domestically, it may need to find an alternate manufacturer for the blood collection set, IV catheter, Patient Safe syringe, 0.5mL insulin syringe, 0.5mL autodisable syringe, and 2mL, 5mL, and 10mL syringes. Even with increased domestic production, the Company may not be able to avoid a disruption in supply.
 On September 13, 2024, the Office of the U.S. Trade Representative ("USTR") revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 of the Trade Act of 1974. Among those products included were syringes and needles, at a rate of 100 %. Additionally, effective February 4th and March 4th of 2025, tariffs on Chinese imports were increased by an aggregate total of 20 %. The increase of 20 % applied not only to syringes and needles, but to other products imported from China. Tariffs are expected to have a material impact to the Company's results of operations and financial position. The Company is working to lessen the financial impact of the tariffs, including shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint needles to its domestic manufacturing facility.

 Revenue recognition
 The Company recognizes revenue when control of performance obligations passes to the customer, generally when the product ships. Payments from customers with approved credit terms are typically due 30 days from the invoice date. Under certain contracts, revenue is recorded on the basis of sales price to distributors, less contractual pricing allowances. Contractual pricing allowances consist of: (i) rebates granted to distributors who provide tracking reports which show, among other things, the facility that purchased the products, and (ii) a provision for estimated contractual pricing allowances for products for which the Company has not received tracking reports. When rebates are issued, they are applied against the customer's receivable balance. Distributors receive a rebate for the difference between the Wholesale Acquisition Cost and the appropriate contract price as reflected on a tracking report provided by the distributor to the Company. If product is sold by a distributor to an entity that has no contract, there is a standard rebate (lower than a contracted rebate) given to the distributor. One of the purposes of the rebate is to encourage distributors to submit tracking reports to the Company. The provision for contractual pricing allowances is recognized in the period the related sales are recognized and is reviewed at the end of each quarter and adjusted for changes in levels of products for which there is no tracking report. Additionally, if it becomes clear that tracking reports will not be provided by individual distributors, the provision is further adjusted. The estimated contractual allowance is included in Accounts payable in the Balance Sheets and deducted from Revenues in the Statements of Operations. Accounts payable included estimated contractual allowances for $ 2.1 million as of December 31, 2024 and 2023. The terms and conditions of contractual pricing allowances are governed by contracts between the Company and its distributors. Revenue for shipments directly to end-users is recognized when title and risk of ownership pass from the Company. End-users do not receive any contractual allowances on their purchases. Any product shipped or distributed for evaluation purposes is expensed.
 The Company provides product warranties that: i) the products are fit for medical use as generally defined within the boundaries of United States FDA approval; ii) the products are not defective; and iii) the products will conform to the descriptions set forth in their respective labeling, provided that they are used in accordance with such labeling and the Company's written directions for use. The Company has historically not incurred significant warranty claims.
 The Company's domestic return policy provides that a customer may return incorrect shipments within 10 days following arrival at the distributor's facility. In all such cases, the distributor must obtain an authorization code from the Company and affix the code to the returned product.
 The Company's domestic return policy also generally provides that a customer may return product that is overstocked. Overstocking returns are limited to two times in each 12 -month period up to 1 % of distributor's total purchase of products for the prior 12 -month period. All product overstocks and returns are subject to inspection and acceptance by the Company. The Company has not historically incurred significant returns.
 On February 5, 2024, the Company initiated a voluntary recall of its EasyPoint Needle lot number K220402 which was shipped within the U.S. between July 20, 2022 and September 20, 2023. The Company shipped 477,600 units of the products into the market and is working with customers and distributors to determine how many of the units remain unused and subject to the recall. The recall is due to the possible detachment of the needle cannula from the needle holder, which could result in serious injury. The Company has advised its customers and distributors to review their inventory for the affected products, segregate and quarantine the affected products, discontinue any distribution of the affected products, inform all personnel not to use the affected products, and report and return remaining inventory to the Company. The Company submitted a Removal Report with the U.S. Food and Drug Administration and has continued to provide monthly updates. The Company estimated that the potential expense related to the recall was approximately $ 116 thousand in 2023. The recall was concluded as of December 2024. Therefore, no amount is accrued for the recall as of December 31, 2024. Since the initiation of the voluntary recall, all reasonable efforts have been made to remove EasyPoint Needle lot K220402 from the market in accordance with the recall strategy. We believe the recall is complete and we have requested termination of the voluntary recall from the FDA. The Medical Devices and Radiological Health Risk Mitigation and Response Branch has: confirmed our request for termination, notified us that the division is currently experiencing a severe backlog of termination requests which are being processed in the order they are received and informed us that once the termination process begins, they will follow up with us concerning any additional questions they may have.

 The Company's international distribution agreements generally do not provide for any returns.
 The Company periodically recognizes revenue from licensing agreements of its intellectual property. Such licensing agreements provide the licensee with right to use the Company's intellectual property. The Company accounts for revenue generated under these licensing agreements in accordance with ASC 606. A license may be perpetual or time limited in its application. The Company has concluded that its licensing agreement is distinct as the customer can benefit from the license on their own. In accordance with ASC 606, the licensing agreement is considered functional as it is without professional services, updates and technical support. The Company has determined the current licensing agreement is sales-based or usage-based as defined in ASC 606. In accordance with ASC 606, the Company recognizes revenue from sales-based or usage-based license at the later of a) subsequent sale or usage occurrence or b) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). The Company recognized $ 189 thousand and $ 778 thousand in licensing fees for years ended December 31, 2024 and 2023, respectively. No licensing fees were recognized for the year end December 31, 2022. If the Company licenses its products for sale and the customers of the sublicensee are not known to the Company, the Company is obligated to pay Thomas J. Shaw, the owner of certain patented technology, fifty percent ( 50 %) of such revenue pursuant to the terms of the Technology License Agreement between the Company and Mr. Shaw.
 Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:

 For the year ended December 31, 2024:

 Blood

 Collection

 EasyPoint

 Other

 Total

 Geographic Segment

 Syringes

 Needles

 Revenue

 U.S. sales

 $

 19,491,747

 1,259,289

 8,595,794

 27,315

 $

 29,374,145

 North and South America sales (excluding U.S.)

 1,895,393

 59,040

 6,240

 1,960,769

 Other international revenue

 1,242,748

 166,222

 293,352

 12,297

 1,714,619

 Total

 $

 22,629,888

 $

 1,425,607

 $

 8,948,186

 $

 45,852

 $

 33,049,533

 For the year ended December 31, 2023:

 Blood

 Collection

 EasyPoint

 Other

 Total

 Geographic Segment

 Syringes

 Needles

 Revenue

 U.S. sales

 $

 26,119,940

 1,414,783

 7,031,798

 33,233

 $

 34,599,754

 North and South America sales (excluding U.S.)

 5,858,726

 —

 —

 226,440

 6,085,166

 Other international sales

 2,176,674

 511,788

 216,944

 6,600

 $

 2,912,006

 Total

 $

 34,155,340

 $

 1,926,571

 $

 7,248,742

 $

 266,273

 $

 43,596,926

 For the year ended December 31, 2022:

 Blood

 Collection

 EasyPoint

 Other

 Total

 Geographic Segment

 Syringes

 Needles

 Revenue

 U.S. sales (excluding U.S. government)

 29,283,122

 $

 2,685,785

 $

 4,481,202

 $

 42,166

 $

 36,492,275

 Sales to U.S. government

 15,731,136

 —

 —

 —

 15,731,136

 North and South America sales (excluding U.S.)

 28,720,378

 —

 2,608

 403,834

 29,126,820

 Other international sales

 13,004,225

 268,064

 190,468

 5,950

 13,468,707

 Total

 86,738,861

 $

 2,953,849

 $

 4,674,278

 $

 451,950

 $

 94,818,938

 Income taxes
 The Company evaluates tax positions taken or expected to be taken in a tax return for recognition in the financial statements based on whether it is "more-likely-than-not" that a tax position will be sustained based upon the technical merits of the position. Measurement of the tax position is based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.
 The Company provides for deferred income taxes through utilizing an asset and liability approach for financial accounting and reporting based on the tax effects of differences between the financial statement and tax bases of assets and liabilities, based on enacted rates expected to be in effect when such differences reverse in future periods. Deferred tax assets are periodically reviewed for realizability.
 As of December 31, 2024, Management concluded that a $ 9.1 million valuation allowance is needed on the net deferred tax asset.
 Management concluded that a $ 283 thousand valuation allowance was needed for state net operating losses as of December 31, 2023 and 2022.
 Earnings per share
 The Company computes basic earnings per share ("EPS") by dividing net earnings for the period (adjusted for any cumulative dividends for the period) by the weighted average number of common shares outstanding during the period. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect, if any, of the common stock deliverable pursuant to stock options and/or common stock issuable upon the conversion of convertible preferred stock.

 The calculation of diluted EPS under the treasury stock method included the following shares in 2024, 2023, and 2022:

 2024

 2023

 2022

 Common stock underlying issued and outstanding stock options

 —

 15,040

 65,597

 —

 15,040

 65,597

 Preferred stock was excluded from the calculation of diluted EPS because the effect was antidilutive.

 The potential dilution, if any, is shown on the following schedule:

 2024

 2023

 2022

 Net income (loss)

 $

 $

 $

 Preferred stock dividend requirements

 ( 230,444)

 ( 231,946)

 ( 232,444)

 Income (loss) applicable to common shareholders

 $

 ( 12,116,968)

 $

 ( 7,242,982)

 $

 4,846,113

 Average common shares outstanding

 32,896,348

 Average common and common equivalent shares outstanding — diluted

 32,961,945

 Basic earnings (loss) per share

 $

 ( 0.40)

 $

 ( 0.24)

 $

 0.15

 Diluted earnings (loss) per share

 $

 ( 0.40)

 $

 ( 0.24)

 $

 0.15

 Shipping and handling costs

 The Company classifies shipping and handling costs as part of Cost of sales in the Statements of Operations.

 Share-based Compensation
 The Company's share-based payments are accounted for using the Black-Scholes fair value method. The Company generally records share-based compensation expense on a straight-line basis over the requisite service period. The Company records forfeitures as they occur.
 Self-insured employee benefit costs
 The Company self-insures certain health insurance benefits for its employees under certain policy limits. The Company has additional coverage provided by an insurance company for any individual with claims in excess of $ 100,000 and/or total plan claims in excess of $ 1.4 million for the plan year.
 Research and development costs
 Research and development costs are expensed as incurred.
 Technology Investment Agreement (TIA)
 Effective July 1, 2020, the Company entered into a Technology Investment Agreement ("TIA") with the United States Government Department of Defense, U.S. Army Contracting Command-Aberdeen Proving Ground, Natick Contracting Division & Edgewood Contracting Division (ACC-APG, NCD & ECD) on behalf of the Biomedical Advanced Research and Development Authority (BARDA), as amended, for $ 81,029,518 in government funding for expanding the Company's domestic production of needles and syringes. At the request of the US government, the TIA was transferred to a successor agreement, identified as Other Transaction Agreement in April 2023. Such agreement contains no additional requirements and, for the purposes of this report, the agreement shall continue to be referred to herein as the "TIA". Under this agreement, the Company has made significant additions to its facilities which allows the Company to increase domestic production capacity. For further explanation, please refer to Note 9 – Technology Investment Agreement.
 As reimbursements were received from the U.S. government for expenditures under the TIA, the Company recorded a deferred liability. In 2021, the deferred liability began to be systematically amortized as a gain over the life of the related property, plant, and equipment and is presented as Other income – TIA on the Statements of Operations. For any reimbursements received for expenditures not capitalized as property, plant, and equipment, Other income – TIA was recognized in the same period as the expense.
 Recently Adopted Accounting Pronouncements
 In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure." The amendments expand segment disclosures for public entities by requiring the disclosure of significant segment expenses regularly provided to the chief operating decision maker, along with other new and enhanced disclosures, including those for interim periods. Under ASU 2023-07, public entities with a single reportable segment must provide all disclosures required by this standard, as well as existing segment disclosures under Topic 280, on both an interim and annual basis. The standard is effective for annual periods beginning after December 15, 2023, and for interim periods starting after December 15, 2024, with retrospective application allowed and early adoption permitted. As of December 31, 2024, the Company has adopted ASU 2023-07. While the adoption has not affected the Company's financial statements, it has resulted in additional disclosures.
 Refer to Note 18 - Segment Information for required disclosures.
 In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions", intended to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendment also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. ASU No. 2022-03 is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted.

 For all other entities, it is effective for fiscal years, including interim periods within those fiscal years beginning after December 15, 2024. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the ASU 2022-03 as of January 1, 2024 with no impact on the Company's financial statements.
 Recently Issued Pronouncements
 In November 2024, the FASB issued ASU 2024-03, "Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." This update enhances the requirements for public companies to provide more detailed and structured disclosures of their expenses, aiming to improve transparency in financial reporting. The new guidance is effective for fiscal reporting periods beginning after December 15, 2026, and for interim periods starting after December 15, 2027. Early adoption is permitted for fiscal financial statements that have not yet been issued or made available for issuance. Companies can choose to apply the amendment either prospectively to periods beginning after the effective date or retrospectively to prior periods presented in their financial statements. The Company is evaluating the adoption of the amendments and the potential impact it may have, if any, on its financial statements.
 In March 2024, the FASB issued ASU 2024-02, "Codification Improvements — Amendments to Remove References to the Concepts Statements", which amends the Codification to remove references to various concepts statements. In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, the references were used in prior Statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for fiscal periods beginning after December 15, 2024. For all other entities, it is effective for fiscal years, including interim periods within those fiscal years beginning after December 15, 2025. Early adoption is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued or made available for issuance. The Company is evaluating the new guidance to determine the impact it may have, if any, on its financial statements.
 In December of 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The updated accounting guidance improves transparency of income tax disclosures, including the disaggregation of existing disclosures related to the effective tax rate reconciliation and income taxes paid. ASU No. 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. For all other entities, it is effective for annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. Prospective application is required, with retrospective application permitted. The Company is evaluating the adoption of the amendments and the potential impact it may have, if any, on its financial statements.

 3. INVENTORIES
 Inventories consist of the following:

 Raw materials

 $

 3,980,650

 $

 4,349,029

 Finished goods

 15,209,103

 13,232,339

 $

 19,189,753

 $

 17,581,368

 4. FAIR VALUE OF FINANCIAL INSTRUMENTS
 ASC 820, "Fair Value Measurements", defines fair value, establishes a framework for measuring fair value and requires additional disclosures regarding certain fair value measurements. ASC 820 establishes a three-tier hierarchy for measuring fair value, as follows:

 Level 1 – quoted market prices in active markets for identical assets and liabilities

 Level 2 – inputs other than quoted prices that are directly or indirectly observable

 Level 3 - unobservable inputs where there is little or no market activity

 The following tables summarize the values of assets designated as Investments in debt and equity securities:

 Level 1

 Level 2

 Level 3

 Total

 Equity securities

 $

 29,259,826

 $

 —

 $

 —

 $

 29,259,826

 Mutual funds

 10,404,218

 —

 —

 10,404,218

 Municipal bonds

 664,264

 —

 —

 664,264

 $

 40,328,308

 $

 —

 $

 —

 $

 40,328,308

 Level 1

 Level 2

 Level 3

 Total

 Equity securities

 $

 18,282,556

 $

 —

 $

 —

 $

 18,282,556

 Mutual funds

 15,656,757

 —

 —

 15,656,757

 Municipal bonds

 681,900

 —

 —

 681,900

 $

 34,621,213

 $

 —

 $

 —

 $

 34,621,213

 The investment assets are held as trading securities and are carried at fair value as of the date of the Balance Sheets. The Company intends to hold these assets for possible future operating requirements.
 The following table summarizes gross unrealized gains and losses from Investments in debt and equity securities:

 Cumulative Unrealized

 Aggregate

 Cost

 Gains

 Losses

 Fair Value

 Equity securities

 $

 24,230,746

 5,029,080

 —

 29,259,826

 Mutual funds

 10,319,644

 84,574

 —

 10,404,218

 Municipal bonds

 636,449

 27,815

 —

 664,264

 $

 35,186,839

 $

 5,141,469

 $

 —

 $

 40,328,308

 Cumulative Unrealized

 Aggregate

 Cost

 Gains

 Losses

 Fair Value

 Equity securities

 $

 24,074,112

 $

 —

 $

 ( 5,791,556)

 $

 18,282,556

 Mutual funds

 15,576,527

 80,230

 —

 15,656,757

 Municipal bonds

 635,425

 46,475

 —

 681,900

 $

 40,286,064

 $

 126,705

 $

 ( 5,791,556)

 $

 34,621,213

 Unrealized gains on investments were $ 10.81 million for the year ended December 31, 2024. Unrealized losses on investments were $ 10.52 million for the year ended December 31, 2023. Unrealized gains on investments were $ 2.34 million for the year ended December 31, 2022.

 5. PROPERTY, PLANT, AND EQUIPMENT
 Property, plant, and equipment consist of the following:

 December 31,

 2024

 2023

 Land

 $

 261,893

 $

 261,893

 Buildings and building improvements

 38,280,191

 37,573,316

 Production equipment

 88,347,336

 88,237,274

 Office furniture and equipment

 5,267,203

 5,149,298

 Construction in progress

 2,475,485

 1,970,386

 134,632,108

 133,192,167

 Accumulated depreciation

 ( 47,283,590)

 ( 39,713,646)

 $

 87,348,518

 $

 93,478,521

 Depreciation expense for the years ended December 31, 2024, 2023, and 2022 was $ 7.6 million; $ 7.5 million; and $ 4.6 million, respectively.

 6. LICENSE AGREEMENT
 In 1995, the Company entered into a license agreement with the Chief Executive Officer of the Company, Thomas J. Shaw, for the exclusive right to manufacture, market, and distribute products utilizing automated retraction technology, which agreement has been amended. This technology is the subject of various patents and patent applications owned by Mr. Shaw. The license agreement provides for quarterly payments of a 5 % royalty fee on gross sales. Additionally, if the Company sublicenses the technology and the sublicensee's customers are not known to the Company, then Mr. Shaw shall be entitled to receive from the Company fifty percent ( 50)% of the royalties actually paid to the Company by such sublicensee. The royalty fee expense is recognized in the period in which it is earned. Royalty fees of $ 2,919,519; $ 3,594,130; and $ 5,937,107 are included in Cost of sales for the years ended December 31, 2024, 2023, and 2022, respectively. Royalties payable under this agreement aggregated $ 789,358 and $ 1,376,555 at December 31, 2024, and 2023, respectively. Gross sales upon which royalties are based were $ 57,019,782; $ 64,883,761; and $ 118,742,140 for 2024, 2023, and 2022, respectively.

 On November 16, 2021, the Company and Mr. Shaw entered into the Third Amendment to Technology License Agreement (the "Amendment"). The Amendment expands the scope of the Technology License Agreement and provides additional protection to the parties in the event of a Hostile Takeover, as defined by the Amendment. Under the Amendment, under certain conditions, Mr. Shaw is granted the unilateral right to terminate the Technology License Agreement or cancel or convert a license thereunder from exclusive to nonexclusive following a Hostile Takeover.

 7. OTHER ACCRUED LIABILITIES
 Other accrued liabilities consist of the following:

 Prepayments from customers

 $

 376,565

 $

 201,492

 Accrued professional fees

 221,475

 320,899

 Current portion – preferred stock repurchase

 6,000

 6,000

 Other accrued expenses

 269,214

 102,180

 Total

 $

 873,254

 $

 630,571

 8. LONG-TERM DEBT
 Long-term debt consists of the following:

 December 31,

 2024

 2023

 Loan from American First National Bank. Maturity date is April 10, 2028. The loan, in the original amount of $ 4,209,608, provided funding for the expansion of the warehouse, additional office space, and a new controlled environment. The loan is secured by the Company's land and buildings. The interest rate is equal to prime rate plus 0.25 %, not to be less than 5.0 %. The interest rate was 7.75 % at December 31, 2024.

 $

 1,232,522

 $

 1,537,510

 Less: current portion

 ( 332,480)

 ( 303,991)

 $

 900,042

 $

 1,233,519

 The fair value of long-term liabilities, based on Management's estimates, approximates their reported values.

 The aggregate maturities of long-term debt as of December 31, 2024, are as follows:

 2025

 $

 332,480

 2026

 363,205

 2027

 396,770

 2028

 140,067

 $

 1,232,522

 9. TECHNOLOGY INVESTMENT AGREEMENT

 Effective July 1, 2020, the Company entered into the Technology Investment Agreement (TIA) with the U.S. government to expand the Company's manufacturing capacity for hypodermic safety needles in response to the worldwide COVID-19 global pandemic. The award is an expenditure-type TIA, whereby the U.S. government has made payments to the Company for the Company's expenditures for equipment and supplies related to the expansion. The Company's contributions under the terms of the TIA include providing facilities, technical expertise, labor and maintenance for the TIA-funded equipment for a ten -year term. In May of 2021, the Company and the U.S. government amended the TIA agreement to include two additional assembly lines and additional controlled environment space.
 The Company has received all equipment, has completed all property construction required by the TIA, and all reimbursement requests have been submitted. No further amounts for expansion under the TIA are expected to be submitted or collected.
 At the request of the US government, the TIA was transferred to a successor agreement, identified as Other Transaction Agreement in April 2023. Such agreement contains no additional requirements, and, for the purposes of this report, the agreement shall continue to be referred to herein as the "TIA". The successor agreement governs ongoing terms established by the TIA until June 30, 2030, which includes maintenance of equipment, availability of capacity, and US government preference in the event of a public health emergency.
 Under the TIA, reimbursable amounts are reflected as Other long-term liabilities on the Balance Sheets until the time the deferred income can be systematically amortized over a period matching the useful life of the purchased assets. Other long-term liabilities from the TIA were $ 63,872,553 and $ 69,773,538 at December 31, 2024 and 2023, respectively.

 10. COMMITMENTS AND CONTINGENCIES

 On November 7, 2019, the Company filed a lawsuit in the 44 th District Court of Dallas County, Texas (No. DC-19-17946) against Locke Lord, LLP and Roy Hardin in connection with their legal representation of the Company in its previous litigation against Becton, Dickinson and Company ("BD"). The Company alleged that the defendants breached their fiduciary duties, committed malpractice, and were negligent in their representation of the Company. The Company seeks actual and exemplary damages, disgorgement, costs, and interest. On September 2, 2022, the Company filed a Second Amended Petition alleging legal malpractice and negligence. On February 20, 2024, the Defendants filed another Motion for Summary Judgment on the Company's remaining claim of legal malpractice. A hearing on that Motion for Summary Judgment was held on April 18, 2024 and an order denying Defendants' Motion was signed May 10, 2024. A new trial date has been set for June 2, 2025.

 On September 26, 2024, the Company filed a lawsuit in the United States Court of International Trade against the United States of America, the Office of the United States Trade Representative, Trade Representative Katherine Tai, U.S. Customs & Border Protection, and U.S. Customs & Border Protection Acting Commissioner Troy Miller. Relief sought included preliminary injunctions on recently enacted tariffs and, ultimately, a decision that the tariffs be set aside, as well as certain costs, fees, and other relief. The Company withdrew its complaint, and the case was dismissed effective January 8, 2025.

 11. INCOME TAXES
 The provision (benefit) for income taxes consists of the following:

 For the Years Ended December 31,

 2024

 2023

 2022

 Current tax provision (benefit)

 Federal

 $

 ( 33,734)

 $

 33,734

 $

 1,448,000

 State

 7,893

 ( 65,529)

 ( 8,711,302)

 Total current provision (benefit)

 ( 25,841)

 ( 31,795)

 ( 7,263,302)

 Deferred tax provision (benefit)

 Federal

 8,285,927

 ( 1,855,875)

 3,717,559

 State

 106,104

 ( 17,491)

 3,629,613

 Total deferred tax provision (benefit)

 8,392,031

 ( 1,873,366)

 7,347,172

 Total income tax provision

 $

 8,366,190

 $

 ( 1,905,161)

 $

 83,870

 The Company uses the recognition and measurement provisions of the FASB ASC Topic 740, Income Taxes ("Topic 740"), to account for income taxes. The provisions of Topic 740 require a company to record a valuation allowance when the "more likely than not" criterion for realizing net deferred tax assets cannot be met. Furthermore, the weight given to the potential effect of such evidence should be commensurate with the extent to which it can be objectively verified. The Company reviewed the operating results, as well as all of the positive and negative evidence related to realization of such deferred tax assets, to evaluate the need for a valuation allowance. As a result of this review, as of December 31, 2024, the Company concluded that a $ 9.1 million valuation is needed on the net deferred tax asset.
 As of December 31, 2023, the Company had federal net operating losses of $ 20.8 million with no expiration date and state net operating losses of $ 4.9 million which will begin to expire in 2029.
 Utilization of the federal net operating loss carry forwards and credits may be subject to a substantial annual limitation due to the ownership change limitations under Internal Revenue Code Section 382. State net operating losses and credits are subject to limitations under similar rules.
 Deferred taxes are provided for those items reported in different periods for income tax and financial reporting purposes. The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below:

 December 31,

 2024

 2023

 Deferred tax assets

 Net operating loss carry forwards

 $

 8,466,565

 $

 4,654,612

 Accrued expenses and reserves

 647,654

 782,233

 Employee stock option expense

 13,311

 13,311

 Inventories

 345,926

 299,276

 Deferred income – TIA contract

 13,495,321

 14,742,111

 Capital loss

 269,651

 188,270

 Interest expense limitation

 -

 —

 Deferred tax assets

 23,238,428

 20,679,814

 Deferred tax liabilities

 Unrealized gains/losses

 ( 1,088,481)

 1,194,734

 Property, plant, and equipment

 ( 13,046,294)

 ( 13,199,805)

 Deferred tax liabilities

 ( 14,134,775)

 ( 12,005,071)

 Net deferred assets

 9,103,653

 8,674,743

 Valuation allowance

 ( 9,103,653)

 ( 282,713)

 Net deferred tax assets

 $

 $

 8,392,030

 *Certain totals may not reconcile due to rounding.

 Deferred income tax calculations reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their tax bases, as well as from net operating loss carry forwards, and are stated at the U.S. tax rate of 21 %. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years.
 Deferred tax assets are periodically reviewed for realizability. The Company establishes a valuation allowance for its net deferred tax asset when future taxable income is not reasonably assured. As of December 31, 2023 and 2022, the Company determined that a $ 283 thousand valuation allowance was needed for the state net operating losses.
 Under the Tax Cuts and Jobs Act, net operating losses incurred after December 31, 2017 can only offset 80% of taxable income. However, these net operating losses may be carried forward indefinitely instead of limited to twenty years under previous tax law. Carryback of these losses is no longer permitted.
 The CARES Act temporarily removed the 80% of taxable income limitation to allow NOL carryforwards to fully offset income. For tax years beginning after 2021, the Company can take: (1) a 100% deduction of NOLs arising in tax years prior to 2018, and (2) a deduction limited to 80% of modified taxable income for NOLs arising in tax years after 2017.
 A reconciliation of the federal statutory corporate tax rate to the Company's effective tax rate is as follows:

 December 31,

 2024

 2023

 2022

 U.S. statutory federal tax rate

 21.0

 21.0

 %

 21.0

 %

 State tax, net of federal tax

 ( 0.6)

 0.8

 1.0

 Change in valuation allowance

 ( 250.6)

 —

 5.5

 Valuation Allowance

 —

 ( 0.2)

 Stock options

 —

 —

 10.8

 Section 162(m); Limit on Compensation

 ( 0.8)

 ( 0.2)

 30.9

 State rate change

 —

 —

 ( 75.1)

 Return-to-provision and other

 ( 6.7)

 0.1

 3.7

 Effective tax rate

 ( 237.7)

 %

 21.5

 %

 1.6

 %

 During 2022, the Company engaged tax consultants to perform a nexus study in order to determine if its activities in certain states were subject to previously estimated tax liabilities. As a result of the study, the Company determined that its activities in those states are protected by P.L. 86-272 and revised its estimates for state taxes. The Company has further determined that it is more likely than not that the various state jurisdictions will agree that the Company's activities are protected under P.L. 86-272 and the revised estimates for refund applications are appropriate.

 The Company files income tax returns in the U.S. federal jurisdiction and in various state and local jurisdictions. The Company's federal income tax returns for all tax years ended on or after December 31, 2009, remain subject to examination by the Internal Revenue Service. The Company's state and local income tax returns are subject to examination by the respective state and local authorities over various statutes of limitations, most ranging from three to five years from the date of filing.

 12. DIVIDENDS
 In June 2021, the Board of Directors approved payments to its Series II, Series III, and former Series IV and Series V Class B Preferred Shareholders in the cumulative amount of $ 5,056,945 representing all current dividends, dividends in arrears, as well as dividends still owed to shareholders who converted their preferred stock in the past. The dividends were paid on July 22, 2021 to all shareholders who had been contacted and confirmed as the rightful owner entitled to payment. The Company has not yet established contact with all former shareholders, most of whom converted their shares prior to 2001. The Company is continuing its efforts to establish contact with approximately 90 former shareholders who are entitled to approximately $ 1.4 million. This, along with the current declared dividends, are reflected in Dividends payable on the Balance Sheets.

 A payment of $ 39,050 was paid within one month of each quarter's end in 2024, 2023, and 2022 to Series II preferred shareholders. As of the fourth quarter of 2023 and for all quarters of 2024, a payment of $ 18,561 was made to Series III shareholders within one month of each quarter's end. Series III preferred shareholders were paid a cash dividend of $ 39,495 in January 2022 and $ 19,061 within one month of each remaining quarter's end in 2022 as well as in the first three quarters of 2023.

 13. STOCKHOLDERS' EQUITY
 Preferred Stock
 The Company is authorized to issue 5,000,000 shares of Preferred Stock Class A with a par value of One Dollar ($ 1.00) per share; 5,000,000 shares of Preferred Stock Class B with a par value of One Dollar ($ 1.00) per share; and 5,000,000 shares of Preferred Stock Class C with a par value of One Dollar ($ 1.00) per share.
 The Company has one class of Preferred Stock outstanding: Class B Convertible Preferred Stock ("Class B Stock"). The Class B Stock has two series: Series II and Series III. Series I, Series IV, and Series V were cancelled by Board resolution effective March 16, 2021.
 The Class B Series II and III stock had 156,200 and 74,245 shares outstanding, respectively, at December 31, 2024. The remaining 4,769,555 authorized shares have not been assigned a series.
 Series II Class B Stock
 There were 156,200 shares of $ 1 par value Series II Class B Stock outstanding at December 31, 2024 and 2023. Holders of Series II Class B Stock are entitled to receive a cumulative annual dividend of $ 1.00 per share, payable quarterly if declared by the Board of Directors. Holders of Series II Class B Stock generally have no voting rights until dividends are in arrears and unpaid for twelve consecutive quarters. In such case, the holders of Series II Class B Stock have the right to elect one-third of the Board of Directors of the Company. The Company paid dividends of $ 156,200 in each of 2024 and 2023. At December 31, 2024, no dividends were in arrears.
 Series II Class B Stock is redeemable at the option of the Company at a price of $ 15.00 per share plus all unpaid dividends. Each share of Series II Class B Stock may, at the option of the stockholder, be converted to one share of Common Stock. No shares were converted in 2024 or 2023. In the event of voluntary or involuntary dissolution, liquidation, or winding up of the Company, holders of Series II Class B Stock then outstanding are entitled to $ 12.50 per share, plus all unpaid dividends, prior to any distributions to holders of Series III Class B Stock or Common Stock.
 Series III Class B Stock
 There were 74,245 shares of $ 1 par value Series III Class B Stock outstanding at December 31, 2024 and 2023, respectively. Holders of Series III Class B Stock are entitled to receive a cumulative annual dividend of $ 1.00 per share, payable quarterly if declared by the Board of Directors. The Company paid dividends of $ 74,245 and $ 76,245 in 2024 and 2023, respectively. At December 31, 2024, no dividends were in arrears.
 Series III Class B Stock is redeemable at the option of the Company at a price of $ 15.00 per share, plus all unpaid dividends. Each share of Series III Class B Stock may, at the option of the stockholder, be converted to one share of Common Stock. 2,000 shares were redeemed in 2023. No shares were converted in 2024 or 2023. In the event of voluntary or involuntary dissolution, liquidation, or winding up of the Company, holders of Series III Class B Stock then outstanding are entitled to $ 12.50 per share, plus all unpaid dividends, after distribution obligations to Series II Class B Stock have been satisfied and prior to any distributions to holders of Common Stock.

 Common stock
 The Company is authorized to issue 100,000,000 shares of no par value Common Stock, of which 29,937,159 shares were outstanding at December 31, 2024 and 2023. At December 31, 2024 and 2023, 4,087,145 shares were held as treasury stock and were not deemed outstanding. Additionally, as of December 31, 2024, a total of 376,395 shares of Common Stock were issuable upon the conversion of Preferred Stock and the exercise of stock options.

 14. TREASURY STOCK
 The Company entered into a repurchase plan (the "Plan") dated June 4, 2021 with an independent broker for the purchase of up to $ 10 million of the Company's Common Stock. The Plan was terminated on April 14, 2022. A total of 1,087,145 shares were purchased under the Plan for a total purchase price of $ 8.1 million.

 The Company entered into a private stock repurchase agreement effective December 2022 for the purchase of 3.0 million shares of Common Stock at $ 1.60 per share for an aggregate purchase price of $ 4.8 million.

 The Company accounts for the purchased shares under the cost method as Common Stock Held in Treasury – at cost, which represents the cost of the shares and, if applicable, the cost of acquiring the shares through the Company's broker.

 15. RELATED PARTY TRANSACTIONS
 The Company has a license agreement with the Chief Executive Officer of the Company. See Note 6.

 On December 26, 2022, the Company approved the repurchase of three million shares of stock at $ 1.60 per share from BML Investment Partners, L.P., a 10 % stockholder at the time of the transaction. BML Investment Partners, L.P. was a related party only by virtue of its stock ownership.

 16. STOCK OPTIONS
 Stock options
 Options for the purchase of 3,649,508 shares of Common Stock have been issued under the 2008 Stock Option Plan. Options for the purchase of 145,950 shares under the 2008 Stock Option Plan were outstanding as of December 31, 2024. No shares are available for future issuance under the 2008 Stock Option Plan, which expired July 25, 2018.
 In the year ended December 31, 2021, three officers were granted options for the purchase of a total of 1,350,000 shares under the 2021 Stock Option Plan. The options had a ten -year term and were to vest in their entirety three years from the grant date. The fair value of the 2021 grant was $ 10.21 per share using the Black-Scholes option pricing model with a risk-free rate of 1.20 %, an exercise price of $ 13.00 per share and a volatility factor of 92.66 %. All such options were terminated on December 19, 2022. No options are currently outstanding under the 2021 Stock Option Plan, and none were granted in 2023 or 2024. Options for the purchase of 2,000,000 shares of Common Stock are available for future issuance under the 2021 Stock Option Plan.

 FASB Accounting Standards Codification Topic 718, Compensation—Stock Compensation (ASU 718), provides accounting guidance and treatment of share-based compensation. ASC 718-20-35-9 provides that a cancellation of an award that is not accompanied by the concurrent grant of (or offer to grant) a replacement award or other valuable consideration shall be accounted for as a repurchase for no consideration. Accordingly, any previously unrecognized compensation cost shall be recognized at the cancellation date. Under this guidance, the Company accelerated the recognition of all future stock option expense related to the terminated option grants. The impact to the financial statements for the year ended December 31, 2022 was the recognition of an additional $ 5.5 million in stock option expense.
 The Compensation and Benefits Committee administers the Company's stock option plans.

 Stock option exercises
 Stock options were exercised by the Company's employees and directors during 2022, and, consequently, a total of 11,200 shares of Common Stock were issued for an aggregate payment to the Company of $ 13,800 to exercise such options. No stock options were exercised in 2023 or 2024.
 Director, officer, and employee options
 A summary of Director, officer, and employee options granted and outstanding under the 2008 Stock Option Plan is presented below:

 2024

 2023

 2022

 Weighted

 Weighted

 Weighted

 Average

 Average

 Average

 Exercise

 Exercise

 Exercise

 Price

 Price

 Price

 Outstanding at beginning of period

 $

 2.06

 $

 2.06

 173,050

 $

 2.06

 Granted

 —

 $

 —

 —

 $

 —

 —

 $

 —

 Exercised

 —

 $

 —

 —

 $

 —

 ( 11,200)

 $

 1.23

 Forfeited

 ( 1,200)

 $

 2.75

 —

 $

 —

 ( 14,700)

 $

 2.75

 Outstanding at end of period

 145,950

 $

 2.05

 $

 2.06

 $

 2.06

 Exercisable at end of period

 145,950

 $

 2.05

 $

 2.06

 $

 2.06

 The following table summarizes information about Director, officer, and employee options outstanding under the 2008 Stock Option Plan at December 31, 2024:

 Weighted Average

 Exercise Prices

 Shares Outstanding

 Remaining Contractual Life

 Shares Exercisable

 $

 1.05

 60,000

 1.99

 60,000

 $

 2.75

 85,950

 1.69

 85,950

 Non-employee options

 There were no non-director and non-employee options outstanding from 2022 - 2024.

 Stock-based Compensation
 No stock-based compensation expense was recorded in 2023 or 2024.

 On December 19, 2022, the Company terminated all stock option awards issued under the 2021 Stock Option Plan, causing the acceleration of the recognition of future stock option expense in the amount of $ 5.5 million. The Company recorded a total of $ 10.1 million in stock-based compensation expense in 2022.

 Options Pricing Models – Assumptions
 The expected life is based on the Company's historical experience with option exercise trends. The assumptions for expected volatility are based on a calculation of volatility over the five years preceding the grant date. Risk-free interest rates are set using grant-date U.S. Treasury yield curves. In its calculations, the Company assumed no dividends. The Company elected a policy to account for forfeitures as they occur, rather than on an estimated basis.

 17. 401(k) PLAN
 The Company implemented an employee savings and retirement plan (the "401(k) Plan") in 2005 that is intended to be a tax-qualified plan covering substantially all employees. The 401(k) Plan is available to all employees on the first day of the month after 90 days of service. Under the terms of the 401(k) Plan, employees may elect to contribute up to 88 % of their compensation, or the statutory prescribed limit, if less. The Company may, at its discretion, match employee contributions. For 2022-2024, the Company matched each participant's elective deferrals up to 2 % of the participant's compensation for the pay period. The total match was $ 239,569; $ 240,635; and $ 241,398 in 2024, 2023, and 2022, respectively.

 18. BUSINESS SEGMENT
 The Company operates in a single reportable segment, referred to as safety medical syringes and other safety medical devices. The business is managed by the chief executive officer who is the Chief Operating Decision Maker (CODM). The CODM evaluates segment performance based on operating income (loss) for purposes of allocating resources and evaluating financial performance. The accounting policies of our single reportable segment are the same as those for the Company as a whole.

 The following are summaries of the Company's sales and long-lived assets by geography:

 2024

 2023

 2022

 U.S. sales

 $

 29,374,145

 $

 34,599,754

 $

 36,492,275

 Sales to U.S. government

 —

 —

 15,731,136

 North and South America sales (excluding U.S.)

 1,960,769

 6,085,166

 29,126,820

 Other international sales

 1,714,619

 2,912,006

 13,468,707

 Total sales

 $

 33,049,533

 $

 43,596,926

 $

 94,818,938

 Long-lived assets

 U.S.

 $

 83,373,876

 $

 89,237,030

 International

 3,974,642

 4,241,491

 Total

 $

 87,348,518

 $

 93,478,521

 Shipments to international customers generally require a prepayment either by wire transfer or an irrevocable confirmed letter of credit. The Company does extend credit to international customers on some occasions depending upon certain criteria, including, but not limited to, the credit worthiness of the customer, the stability of the country, banking restrictions, and the size of the order. All transactions are in U.S. currency.

 19. PRIVATE EXCHANGES AND REDEMPTION

 In 2020, the Company entered into several agreements with shareholders to purchase its outstanding Class B Convertible Preferred Stock. The consideration for these purchases consisted of both cash and Common Stock. In addition, in each such transaction, the preferred shareholder counterparty waived all rights to unpaid dividends in arrears. The aggregate cash consideration equaled $ 3,786,000, of which $ 482,670 was paid in 2020 with the rest payable over a three-year period. Equal installment payments were paid in February 2021, 2022, and 2023 in the amount of $ 1,101,110 each.

 Effective November 2023, the Company entered into a privately negotiated transaction with a preferred shareholder to redeem 2,000 shares of Series III Class B Stock for a purchase price equal to approximately $ 6 thousand.

 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
 There were no reportable disagreements with accountants on accounting and financial disclosures.

 Item 9A. Controls and Procedures.
 Disclosure Controls and Procedures
 Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (the "Exchange Act"), Management, with the participation of our President, Chairman, and Chief Executive Officer, Thomas J. Shaw (the "CEO"), and our Vice President and Chief Financial Officer, John W. Fort III (the "CFO"), acting in their capacities as our principal executive and financial officers, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Exchange Act. The term disclosure controls and procedures means controls and other procedures that are designed to ensure that information required to be disclosed by us in our periodic reports is: i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's (the "SEC") rules and forms; and ii) accumulated and communicated to our Management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based upon this evaluation, the CEO and CFO concluded that, as of December 31, 2024, our disclosure controls and procedures were not effective, as discussed below.
 Management's Annual Report on Internal Control over Financial Reporting
 Management is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rule 13a-15(f) under the Exchange Act. The term internal control over financial reporting means a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, Management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and dispositions of assets; (ii) provide reasonable assurance that our transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of Management and Directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements. Management used the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting as required by paragraph (c) of Rule 13a-15 under the Exchange Act. Based on that evaluation, Management concluded that the Company's internal control over financial reporting was not effective as of December 31, 2024.
 A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
 Management identified the following material weaknesses in internal controls as of December 31, 2024:

 The Company did not maintain the risk assessment and control activities components of the COSO framework. These material weaknesses gave rise to the following control deficiency, which was also determined to be a material weakness.

 The Company did not design and maintain effective controls to timely document and evaluate revenue contract terms and the related revenue recognition accounting conclusions when entering into significant revenue contracts.

 Limitations on Effectiveness of Controls

 Our Management, including the CEO and CFO, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all instances of fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met.
 Remediation of the Material Weaknesses in Internal Control over Financial Reporting
 In light of the material weaknesses in internal control over financial reporting, Management intends to enhance our review and analysis of contractual modifications with our customers, utilizing senior members of our accounting team, including the CFO, to identify and properly classify revenue transactions and their impact on our financial statements. Management believes that such enhancements to our review and analysis procedures will prevent errors from occurring, or that potential errors will be discovered and remediated in a timely manner.
 Changes in Internal Control over Financial Reporting
 There have been no changes in our internal control over financial reporting during the fourth quarter of 2024 which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 Item 9B. Other Information.
 No director or officer adopted or terminated a trading arrangement in the fourth quarter of 2024 of the type described by Item 408 of Regulation S-K. As previously reported, on August 22, 2024, Thomas J. Shaw, President, Chairman, and Chief Executive Officer, adopted a written plan for the purchase of Retractable Technologies, Inc. common stock intended to satisfy the affirmative defense conditions of Rule 10b5–1(c). In accordance with the plan, trading began November 20, 2024 and may continue through November 19, 2025 if not earlier terminated. During this period, the plan instructs a broker-dealer to purchase common stock for an aggregate purchase price of up to $800,000 within certain price parameters. Mr. Shaw's purchases pursuant to this plan are reported on forms filed with the SEC pursuant to Section 16(a) of the Securities Exchange Act of 1934.

 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
 None.

 Item 10. Directors, Executive Officers and Corporate Governance.
 The information in the sections "Proposal – The Election of Three Class 1 Directors" and "Corporate Governance" in the 2025 proxy statement is incorporated herein by reference.

 Item 11. Executive Compensation.
 The information in the section "Compensation" in the 2025 proxy statement is incorporated herein by reference.

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
 The information in the section "Security Ownership" in the 2025 proxy statement is incorporated herein by reference. See also Item 5 of Part II of this Annual Report for Equity Compensation Plan Information.

 Item 13. Certain Relationships and Related Transactions, and Director Independence
 The information in the section "Corporate Governance" in the 2025 proxy statement is incorporated herein by reference.

 Item 14. Principal Accounting Fees and Services.
 The information in the section "Accounting Matters" in the 2025 proxy statement is incorporated herein by reference.

 Item 15. Exhibits, Financial Statement Schedules.
 (a) (1) All financial statements: See Retractable Technologies, Inc. Index to Financial Statements on Page F-2.
 (2) Those financial statement schedules required to be filed by Item 8 of this form, and by paragraph (b) below. Schedule II-Schedule of Valuation and Qualifying Accounts for the years ended December 31, 2024, 2023, and 2022:

 Balance at

 Balance at

 beginning of

 end of

 period

 Additions

 Deductions

 period

 Provision for Credit Losses

 Fiscal year ended 2022

 $

 352,217

 $

 322,991

 $

 —

 $

 675,208

 Fiscal year ended 2023

 $

 675,208

 $

 626,940

 $

 411,607

 $

 890,541

 Fiscal year ended 2024

 $

 890,541

 $

 571,682

 $

 794,099

 $

 668,124

 Deferred Tax Valuation

 Fiscal year ended 2022

 $

 —

 $

 $

 —

 $

 Fiscal year ended 2023

 $

 $

 —

 $

 —

 $

 Fiscal year ended 2024

 $

 $

 8,820,940

 $

 —

 $

 9,103,653

 Balance at

 Balance at

 beginning of

 end of

 period

 Additions

 Deductions

 period

 Provision for Rebates

 (A)

 (B)

 (C)

 Fiscal year ended 2022

 $

 6,638,115

 $

 22,978,339

 $

 26,356,187

 $

 3,260,267

 Fiscal year ended 2023

 $

 3,260,267

 $

 20,346,600

 $

 21,410,496

 $

 2,196,371

 Fiscal year ended 2024

 $

 2,196,371

 $

 21,100,390

 $

 21,184,317

 $

 2,112,444

 (A)
 Represents estimated rebates deducted from gross revenues.

 (B)
 Represents rebates credited to the distributor and charge offs against the allowance.

 (C)
 Includes $ 2,112,444; $ 2,196,371; and $ 2,950,155 in Accounts payable for 2024, 2023, and 2022, respectively.

 (3) Exhibits:
 The following exhibits are filed herewith or incorporated herein by reference to exhibits previously filed with the SEC.
 (b) Exhibits

 Exhibit
No.

 Description of Document

 3(i)

 Restated Certificate of Formation with Certificates of Designation, Preferences, Rights and Limitations of Class B Preferred Stock (all Series) (1)

 3(ii)

 Fourth Amended and Restated Bylaws of RTI (2)

 Exhibit
No.

 Description of Document

 4(i)

 Restated Certificate of Formation with Certificates of Designation, Preferences, Rights and Limitations of Class B Preferred Stock (all Series) (3)

 4(vi)

 Description of Securities (4)

 10.1

 Employment Agreement between RTI and Thomas J. Shaw dated as of January 1, 2008 (5)

 10.2

 Technology License Agreement between Thomas J. Shaw and RTI dated the 23 rd day of June, 1995 (6)

 10.3

 First Amendment to Technology License Agreement between Thomas J. Shaw and RTI dated the 3rd day of July, 2008 (7)

 10.4

 Second Amendment to Technology License Agreement between Thomas J. Shaw and Retractable Technologies, Inc. dated as of the 7th day of September, 2012 (8)

 10.5

 Third Amendment to Technology License Agreement between Thomas J. Shaw and Retractable Technologies, Inc. dated as of the 16th day of November, 2021 (9)

 10.6

 Retractable Technologies, Inc. First Amended 2008 Stock Option Plan (10)

 10.7

 Voting Agreement Between Thomas J. Shaw and Suzanne August dated November 8, 2006 (11)

 10.8

 Technology Investment Agreement between RTI and U.S. Department of Defense dated July 1, 2020 (12)

 10.9

 2021 Stock Option Plan (13)

 Retractable Technologies, Inc. Code of Business Conduct and Ethics (14)

 Retractable Technologies, Inc. Code of Business Conduct and Ethics (15)

 31.1

 Certification of Principal Executive Officer (16)

 31.2

 Certification of Principal Financial Officer (17)

 Section 1350 Certifications (18)

 Restated Clawback Policy (19)

 (1) Incorporated herein by reference to RTI's Form 10-K filed on March 31, 2021
 (2) Incorporated herein by reference to RTI's Form 8-K filed on May 13, 2010
 (3) Incorporated herein by reference to RTI's Form 10-K filed on March 31, 2021
 (4) Incorporated herein by reference to RTI's Form 10-K filed on March 30, 2023
 (5) Incorporated herein by reference to RTI's Form 10-Q filed on November 14, 2008
 (6) Incorporated herein by reference to RTI's Registration Statement on Form 10-SB filed on June 23, 2000
 (7) Incorporated herein by reference to RTI's Form 10-K filed on March 31, 2009
 (8) Incorporated herein by reference to RTI's Form 10-Q filed on November 14, 2012
 (9) Incorporated herein by reference to RTI's Form 8-K filed on November 18, 2021
 (10) Incorporated herein by reference to RTI's Form 10-Q filed on November 14, 2014

 (11) Incorporated herein by reference to RTI's Schedule TO filed on October 17, 2008
 (12) Incorporated herein by reference to RTI's Form 10-Q filed on November 16, 2020
 (13) Incorporated herein by reference to RTI's Schedule 14A filed March 31, 2021
 (14) Incorporated herein by reference to RTI's Form 8-K filed on August 17, 2020
 (15) Incorporated herein by reference to RTI's Form 8-K filed on August 17, 2020
 (16) Filed herewith
 (17) Filed herewith
 (18) Filed herewith
 (19) Incorporated herein by reference to RTI's Form 10-K filed on March 29, 2024
 (20) Filed herewith
 (c) Excluded Financial Statement Schedules: None

 Item 16. Form 10-K Summary.
 None.

 SIGNATURES
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 (Registrant)

 By:

 /s/ Thomas J. Shaw

 THOMAS J. SHAW

 CHAIRMAN, PRESIDENT, AND

 CHIEF EXECUTIVE OFFICER

 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 /s/ John W. Fort III

 JOHN W. FORT III

 VICE PRESIDENT, CHIEF FINANCIAL OFFICER, PRINCIPAL ACCOUNTING OFFICER, TREASURER, AND DIRECTOR

 /s/ Amy Mack

 AMY MACK

 DIRECTOR

 /s/ Marco Laterza

 MARCO LATERZA

 DIRECTOR

 /s/ Walter O. Bigby, Jr.

 WALTER O. BIGBY, JR.

 DIRECTOR

 /s/ Darren E. Findley

 DARREN E. FINDLEY

 DIRECTOR